###begin article-title 0
###xml 34 36 34 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn3">S&#8414;</xref>
The Sushi Domains of Secreted GABAB1 Isoforms Selectively Impair GABAB Heteroreceptor Function*Sâƒž
###end article-title 0
###begin p 1
These authors contributed equally.
###end p 1
###begin p 2
###xml 165 191 165 191 <email xmlns:xlink="http://www.w3.org/1999/xlink">bernhard.bettler@unibas.ch</email>
 To whom correspondence should be addressed: Pharmazentrum, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland. Tel.: 41-61-267-1632; Fax: 41-61-267-1628; E-mail: bernhard.bettler@unibas.ch. 
###end p 2
###begin p 3
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 3
###begin p 4
 applies to Author Choice Articles
###end p 4
###begin p 5
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 143 144 139 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 344 347 340 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 356 359 352 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 365 368 361 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 386 389 382 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 538 541 534 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 618 621 614 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 630 633 626 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 737 740 733 736 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 757 759 753 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 1074 1075 1070 1071 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1205 1206 1201 1202 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1266 1267 1262 1263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1374 1377 1370 1373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1468 1470 1464 1466 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 1489 1492 1485 1488 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1591 1592 1587 1588 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1747 1748 1743 1744 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
GABAB receptors are the G-protein-coupled receptors for gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the brain. GABAB receptors are promising drug targets for a wide spectrum of psychiatric and neurological disorders. Receptor subtypes exhibit no pharmacological differences and are based on the subunit isoforms GABAB1a and GABAB1b. GABAB1a differs from GABAB1b in its ectodomain by the presence of a pair of conserved protein binding motifs, the sushi domains (SDs). Previous work showed that selectively GABAB1a contributes to heteroreceptors at glutamatergic terminals, whereas both GABAB1a and GABAB1b contribute to autoreceptors at GABAergic terminals or to postsynaptic receptors. Here, we describe GABAB1j, a secreted GABAB1 isoform comprising the two SDs. We show that the two SDs, when expressed as a soluble protein, bind to neuronal membranes with low nanomolar affinity. Soluble SD protein, when added at nanomolar concentrations to dissociated hippocampal neurons or to acute hippocampal slices, impairs the inhibitory effect of GABAB heteroreceptors on evoked and spontaneous glutamate release. In contrast, soluble SD protein neither impairs the activity of GABAB autoreceptors nor impairs the activity of postsynaptic GABAB receptors. We propose that soluble SD protein scavenges an extracellular binding partner that retains GABAB1a-containing heteroreceptors in proximity of the presynaptic release machinery. Soluble GABAB1 isoforms like GABAB1j may therefore act as dominant-negative inhibitors of heteroreceptors and control the level of GABAB-mediated inhibition at glutamatergic terminals. Of importance for drug discovery, our data also demonstrate that it is possible to selectively impair GABAB heteroreceptors by targeting their SDs.
###end p 5
###begin p 6
###xml 0 83 0 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">The nucleotide sequence(s) reported in this paper has been submitted to the GenBank</italic>
###xml 93 142 84 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/EBI Data Bank with accession number(s) AM418837.</italic>
The nucleotide sequence(s) reported in this paper has been submitted to the GenBanktrade mark/EBI Data Bank with accession number(s) AM418837.
###end p 6
###begin p 7
###xml 44 92 44 92 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">European Community's Seventh Framework Programme</grant-sponsor>
###xml 131 137 131 137 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">201714</grant-num>
###xml 176 200 176 200 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Swiss Science Foundation</grant-sponsor>
###xml 208 222 208 222 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">3100-067100.01</grant-num>
###xml 241 259 241 259 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Novartis Pharma AG</grant-sponsor>
###xml 402 415 402 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported by a grant from the European Community's Seventh Framework Programme (FP7/2007-2013) under Grant Agreement 201714. This study was also supported by the Swiss Science Foundation (Grant 3100-067100.01) and a grant from Novartis Pharma AG. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 7
###begin p 8
The on-line version of this article (available at ) contains supplemental text, three supplemental figures, and three supplemental tables.
###end p 8
###begin p 9
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 9
###begin p 10
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 215 216 215 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 280 282 280 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 350 352 350 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 360 361 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 362 363 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn5">3</xref>
###xml 537 538 537 538 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 569 570 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 698 699 698 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 760 761 760 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 812 814 812 814 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 823 825 823 825 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B2</sub>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 839 841 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 875 876 875 876 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 936 938 936 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 965 968 965 968 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 977 980 977 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 1052 1059 1052 1059 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 1068 1075 1068 1075 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1b,2)</sub>
###xml 1129 1131 1129 1131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 1158 1159 1158 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 1161 1163 1161 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 1164 1166 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 1191 1194 1191 1194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1203 1206 1203 1206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 1309 1312 1309 1312 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1328 1331 1328 1331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 1333 1335 1333 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 1337 1339 1337 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 1531 1533 1531 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 1535 1537 1535 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 1583 1590 1583 1590 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 1599 1606 1599 1606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1b,2)</sub>
###xml 1663 1666 1663 1666 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1675 1678 1675 1678 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 1706 1709 1706 1709 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1709 1712 1709 1712 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1716 1719 1716 1719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1729 1732 1729 1732 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 1732 1735 1732 1735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1739 1742 1739 1742 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1790 1792 1790 1792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1856 1859 1856 1859 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1912 1913 1912 1913 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1940 1943 1940 1943 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1951 1954 1951 1954 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 1965 1967 1965 1967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1968 1970 1968 1970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 2007 2010 2007 2010 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 2129 2132 2129 2132 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 2208 2209 2208 2209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 2244 2246 2244 2246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 1744 1748 <span type="species:ncbi:10090">mice</span>
###xml 1801 1805 <span type="species:ncbi:10090">mice</span>
GABAB receptors mediate pre- and postsynaptic inhibition in the nervous system and are implicated in a variety of disorders, including cognitive impairments, anxiety, depression, and epilepsy (1-3). Presynaptic GABAB receptors prevent neurotransmitter release via inhibition of Ca2+ channels (4) and second messenger-mediated effects downstream of Ca2+ entry (5-8). They are commonly divided into auto- and heteroreceptors depending on whether they control the release of GABA3 or other neurotransmitters, respectively. Postsynaptic GABAB receptors activate Kir3-type K+ channels and generate slow inhibitory postsynaptic currents (IPSCs) that hyperpolarize the cell and shunt excitatory currents (9). Recombinant and native studies showed that functional GABAB receptors are obligate heteromers composed of GABAB1 and GABAB2 subunits (10-13). Molecular diversity in the GABAB receptor system arises from the expression of multiple GABAB1 subunit isoforms. The GABAB1a and GABAB1b isoforms constitute two independently regulated receptor subtypes, GABAB(1a,2) and GABAB(1b,2), whereas the functional role of several secreted GABAB1 isoforms remains unclear (1, 14-17). Structurally, the GABAB1a and GABAB1b isoforms solely differ in their N-terminal ectodomain by a tandem pair of SDs that are present in GABAB1a but not in GABAB1b (18, 19). SDs, also known as complement control modules or short consensus repeats, mediate protein interactions in adhesion molecules and in G-protein-coupled receptors binding to peptide hormones (20, 21). Pharmacological tools that distinguish GABAB(1a,2) and GABAB(1b,2) receptors are lacking; however, the native roles of GABAB1a and GABAB1b were dissociated using GABAB1a-/- (1a-/-) and GABAB1b-/- (1b-/-) mice, which express one or the other isoform (22). These mice revealed that heteroreceptors incorporate the GABAB1a subunit, whereas autoreceptors and postsynaptic GABAB receptors incorporate GABAB1a or GABAB1b subunits (22-24). This suggests that the SDs of GABAB1a bind to protein(s) that localize heteroreceptors at glutamatergic terminals. A protein binding to the first SD of GABAB1a is the extracellular matrix protein fibulin-2, but whether it mediates GABAB receptor localization is unknown (19).
###end p 10
###begin p 11
###xml 38 41 38 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 50 53 50 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 80 82 80 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GABA<sub>B1</sub></italic>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 392 394 392 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 507 508 507 508 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
In addition to the membrane-bound GABAB1a and GABAB1b subunit isoforms, the GABAB1 gene produces several secreted isoforms that all include the SDs (14-16). Secreted isoforms containing SDs were also described for other receptors and shown to exert dominant-negative effects by scavenging the binding partners of the membrane-bound receptor (25, 26). Here, we identified a novel secreted GABAB1 isoform containing the SDs and addressed whether such soluble isoforms have the potential to block neuronal GABAB receptor functions in a dominant-negative manner.
###end p 11
###begin title 12
EXPERIMENTAL PROCEDURES
###end title 12
###begin p 13
###xml 24 27 24 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 0 41 0 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of GABA<sub>B1j</sub> cDNA and mRNA</italic>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 158 160 158 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 365 372 365 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In situ</italic>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 460 463 460 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 128 132 <span type="species:ncbi:10116">rats</span>
###xml 282 287 <span type="species:ncbi:10090">mouse</span>
###xml 307 312 <span type="species:ncbi:10090">mouse</span>
Characterization of GABAB1j cDNA and mRNA-An oligo(dT) primed double-stranded cDNA made from the cortex/cerebellum of 7-day-old rats (34) was screened with a 32P-labeled SD-specific cDNA hybridization probe as described (27). For Northern blot analysis, total RNA was isolated from mouse brain and cultured mouse cortical neurons using TRIzol reagent (Invitrogen). In situ hybridization was performed as described previously (28) using digoxigenin-labeled GABAB1j-specific antisense RNA probes.
###end p 13
###begin p 14
###xml 4 7 4 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 0 26 0 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GABA<sub>B1j</sub> Protein Expression</italic>
###xml 41 44 41 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 89 92 89 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 101 104 101 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 346 348 346 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 489 490 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 697 698 697 698 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 985 988 985 988 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 997 1000 997 1000 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1141 1142 1141 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 1227 1233 <span type="species:ncbi:9986">rabbit</span>
###xml 1334 1340 <span type="species:ncbi:9793">donkey</span>
###xml 1346 1352 <span type="species:ncbi:9986">rabbit</span>
GABAB1j Protein Expression-Because a GABAB1j-specific antibody is lacking, we tagged GABAB1a and GABAB1j with the c-Myc epitope (29) and inserted the cDNAs into the expression vector pCI (Promega). Conditioned medium of transfected HEK293 cells (Lipofectamine 2000, Invitrogen) was collected after 48 h and used to immunoprecipitate secreted GABAB1 protein. Briefly, the medium was incubated with protein G-agarose (Roche Applied Science) for 2 h, precleared by centrifugation at 10,000 x g for 10 min, and incubated overnight with a monoclonal anti-Myc antibody (9E10, Sigma-Aldrich, diluted 1:1000) coupled to protein G-agarose. After five washes in radio immunoprecipitation assay buffer (150 mm NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate containing a protease inhibitor mixture (Roche Applied Science)), immunoprecipitated proteins were eluted from the protein G-agarose using 2x SDS loading buffer, separated on SDS-PAGE, and analyzed by Western blotting. To control for GABAB1a and GABAB1j expression levels, transfected HEK293 cells were lysed in radio immunoprecipitation assay buffer, and the lysate was precleared at 10,000 x g for 10 min and mixed with 2x SDS loading buffer. For Western blot analysis, we used rabbit polyclonal anti-Myc (PRB-150C diluted 1:1000, Covance) and peroxidase-coupled secondary antibodies (donkey anti-rabbit diluted 1:2500, Amersham Biosciences). Blots were developed using the enhanced chemiluminescence detection system (Amersham Biosciences) and exposed to Kodak Bio-Max maximum resolution x-ray films (Sigma-Aldrich).
###end p 14
###begin p 15
###xml 21 24 21 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 90 92 90 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 446 448 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 509 511 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 734 736 731 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 800 802 797 799 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 661 665 <span type="species:ncbi:9913">calf</span>
To detect native GABAB1j protein, we generated the anti-SD monoclonal antibody 43H12. GABAB1-deficient mice (11) were immunized intraperitoneally with 50 mug of GST.SD fusion protein in alum, and after 4 weeks, they were boosted intravenously with 10 mug of GST.SD fusion protein in phosphate-buffered saline. 5 days after boosting, spleen cells were used to generate hybridomas, which were screened for the production of IgG anti-SD antibodies (30). Prior to metabolic labeling, cortical neurons in culture (31) were incubated for 30 min in 15 ml of methionine- and cysteine-free Dulbecco's modified Eagle's medium (Sigma-Aldrich) containing 1% dialyzed fetal calf serum. The cells were then labeled for 5 h with 5 ml of 150 muCi/ml 35S-EXPRESS protein labeling mix (PerkinElmer Life Sciences). GABAB1 proteins with SDs were immunoprecipitated from conditioned cell culture medium and lysed cells (radio immunoprecipitation assay buffer) using anti-SD antibody 43H12. Radiolabeled proteins were revealed by autoradiography after SDS-PAGE.
###end p 15
###begin p 16
###xml 0 3 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>125</sup>I-Tyr-RSDP Binding</italic>
###xml 174 175 174 175 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 325 328 325 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 533 534 533 534 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 557 558 557 558 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 570 571 570 571 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 586 587 586 587 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 590 591 590 591 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 593 594 593 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 601 602 601 602 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 607 608 607 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 615 616 615 616 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 627 628 627 628 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 633 634 633 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 675 676 675 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 959 960 957 958 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 960 963 958 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 1140 1141 1138 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 720 723 <span type="species:ncbi:10116">Rat</span>
###xml 858 864 <span type="species:ncbi:9913">bovine</span>
125I-Tyr-RSDP Binding-Recombinant SD protein (RSDP) and mutant RSDP (mutRSDP) were produced and purified as described (supplemental materials). RSDP was dialyzed against 10 mm MES buffer (pH 6.1, Sigma-Aldrich), concentrated to 0.95 mg/ml by ultrafiltering (anisotropic membrane YM-10 Centricon, Millipore), and labeled with 125I to a specific activity of 1846 Ci/mmol (ANAWA Trading SA). To prepare membranes for competition binding experiments, CHO-K1 (ATCC) and 293FT (Invitrogen) cells were homogenized in Krebs-Tris buffer (20 mm Tris-Cl, pH 7.4, 118 mm NaCl, 5.6 mm glucose, 1.2 mm KH2PO4, 1.2 mm MgSO4, 4.7 mm KCl, 1.8 mm CaCl2) and centrifuged for 30 min at 40,000 x g, and the pellet was resuspended in buffer. Rat cortex synaptic membranes were prepared as described (27). Membranes were suspended in Krebs-Tris buffer supplemented with 0.2% (w/v) bovine serum albumin at a concentration of 200-400 mug/ml. 100-mul aliquots were incubated with 0.5 nm125I-Tyr-RSDP for 90 min at room temperature in the presence or absence of unlabeled RSDP protein. After cooling on ice for 20 min, samples were centrifuged for 30 min at 20,000 x g (4 degreesC). The pellet was rinsed three times with 1 ml of ice-cold buffer, and the radioactivity was determined by Cerenkov counting. Concentration response curves were generated from triplicate determinations (GraphPad).
###end p 16
###begin p 17
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Electrophysiology</italic>
###xml 187 188 186 187 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 217 218 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 228 229 227 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 238 239 237 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 241 242 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 254 255 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 296 297 295 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 304 305 303 304 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 899 900 888 889 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1044 1045 1021 1022 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1084 1085 1061 1062 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1116 1117 1093 1094 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1128 1129 1105 1106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1275 1276 1251 1252 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1356 1357 1332 1333 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1473 1474 1449 1450 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1498 1499 1473 1474 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 2019 2020 1994 1995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2136 2137 2111 2112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2260 2261 2235 2236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2549 2550 2510 2511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2559 2560 2520 2521 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 2619 2621 2580 2582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 2481 2486 <span type="species:ncbi:10090">mouse</span>
Electrophysiology-300-mum-thick horizontal hippocampal slices were prepared from postnatal day 22-28 mice (VT 1000 vibratome, Leica) in cooled artificial cerebro-spinal fluid (ACSF) (in mm: 119 NaCl, 2.5 KCl, 1.3 MgCl2, 2.5 CaCl2, 1.0 NaH2PO4, 26.2 NaHCO3, and 11 glucose) equilibrated with 95% O2, 5% CO2 at pH 7.3. After recovery for >1 h, slices were incubated for 6 h with RSDP (1.0 mug/ml), transferred to the recording chamber, and superfused (2 ml/min) with ACSF at 30-32 degreesC. Visualized whole cell voltage clamp recording was used to measure holding currents (Kir3 channels) and synaptic currents from the somata of CA1 pyramidal neurons. Synaptic currents were evoked by voltage pulses (100 mus, 2-5 V) delivered through a bipolar Pt-Ir electrode (25 mum in diameter) placed in the stratum radiatum. Miniature postsynaptic currents were recorded in the presence of tetrodotoxin (0.5 mum, Latoxan). For measuring miniature and evoked currents, patch electrodes (approximately3 megaohms) were filled with a solution containing, in mm: 30 cesium gluconate, 100 CsCl, 4 MgCl2, 10 creatine phosphate, 3.4 Na2ATP, 0.1 Na3GTP, 1.1 EGTA, and 5 Hepes (pH adjusted to 7.3 with KOH). Adenosine-mediated presynaptic inhibition was measured in the presence of CGP54626 (2 mum). For measuring Kir3 currents, cesium gluconate and CsCl were replaced by 130 mm potassium gluconate. GABAergic and glutamatergic currents were pharmacologically isolated using kynurenic acid (2 mm) and picrotoxin (100 mum), respectively. Neurons were clamped at -50 mV. Currents were amplified (Axopatch 200B, Axon Instruments), filtered at 1 kHz, and digitized at 5 kHz. Miniature excitatory postsynaptic currents (mEPSCs) and miniature inhibitory postsynaptic currents (mIPSCs) were detected and analyzed using MiniAnalysis software (version 6.0.3, Synaptosoft, Decatur, GA). Significant differences between two distributions of mEPSC and mIPSC amplitude and interevent intervals were determined by using the Kolmogorov-Smirnov test, with p < 0.01 indicating significance. Evoked synaptic currents were analyzed using analysis of variance (GraphPad), with p < 0.01 indicating significance. Kir3 currents were statistically analyzed using the nonparametric Mann-Whitney test, with p </= 0.05 indicating significance (INSTAT, version 3.0, GraphPad). The recording of miniature postsynaptic currents in dissociated cultured neurons was as described above. Hippocampal neurons were prepared from 16.5-day mouse embryos and cultured at a density of approximately750 cells/mm2 on poly-l-lysine coated glass coverslips for 3 weeks, as described (31). Neurons with a basal frequency of approximately3 Hz were used in the experiments. The experimenter was blind to the treatment of the hippocampal cultures or the slices. Baclofen and CGP54626 were from Novartis, and all other reagents were from Fluka or Sigma-Aldrich.
###end p 17
###begin p 18
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 37 40 37 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 9 49 9 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of the GABA<sub>B1j</sub> isoform.</bold>
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 102 104 102 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GABA<sub>B1</sub></italic>
###xml 148 151 148 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 157 160 157 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 170 173 170 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 188 191 188 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 338 339 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 371 374 371 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 383 386 383 386 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 449 452 449 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ctx</italic>
###xml 510 512 510 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 542 543 542 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 649 652 637 640 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 681 684 657 660 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 765 768 741 744 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 797 800 761 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 877 887 841 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C, in situ</italic>
###xml 941 944 905 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Top</italic>
###xml 1005 1011 969 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 1144 1149 1108 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CA1/3</italic>
###xml 1167 1169 1131 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DG</italic>
###xml 1189 1191 1153 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MH</italic>
###xml 1218 1220 1182 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GL</italic>
###xml 1243 1245 1207 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ML</italic>
###xml 1280 1290 1244 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bars</italic>
###xml 1298 1301 1262 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 1316 1322 1279 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 1325 1326 1288 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1367 1370 1330 1333 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1372 1378 1335 1341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc-1a</italic>
###xml 1387 1390 1350 1353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1392 1398 1355 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc-1j</italic>
###xml 1430 1440 1393 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cond. med.</italic>
###xml 1628 1631 1591 1594 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1706 1709 1669 1672 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1776 1789 1739 1752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E, left panel</italic>
###xml 1852 1855 1815 1818 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1868 1871 1831 1834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 1921 1923 1884 1886 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 1933 1943 1896 1906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IP anti-SD</italic>
###xml 1995 2000 1958 1963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">input</italic>
###xml 2035 2037 1998 2000 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 2048 2050 2011 2013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 2053 2064 2016 2027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 2187 2190 2150 2153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 2192 2194 2155 2157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">**</sup>
###xml 2204 2207 2167 2170 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 2209 2210 2172 2173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 9 2312 9 2275 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19"><bold>Characterization of the GABA<sub>B1j</sub> isoform.</bold><italic>A</italic>, schematic representation of the 5&#8242; end of the <italic>GABA<sub>B1</sub></italic> gene indicating the exons encoding the GABA<sub>B1a</sub>, GABA<sub>B1b</sub>, and GABA<sub>B1j</sub> isoforms. GABA<sub>B1j</sub> results from an 870-bp extension of exon 4 at its 3&#8242; end (exon 4&#8242;), generating an open reading frame of 687 nucleotides encompassing the two SDs. <italic>B</italic>, Northern blot analysis of GABA<sub>B1a</sub> and GABA<sub>B1j</sub> transcripts. Total RNA extracted from primary mouse cortical (<italic>ctx</italic>) neurons in culture or mouse brain was hybridized to the <sup>32</sup>P-labeled probes indicated in <italic>A</italic>. The pan probe encodes part of the extracellular GABA binding domain and detects &#8764;4.5-kb GABA<sub>B1a</sub> and &#8764;4.1-kb GABA<sub>B1b</sub> transcripts (not resolved). The SD1/2 probe encodes the two SDs and detects GABA<sub>B1a</sub> and &#8764;1.6-kb GABA<sub>B1j</sub> transcripts. The 1j probe encodes 510 nucleotides at the 3&#8242; end of exon 4&#8242;. <italic>C, in situ</italic> hybridization with the digoxigenin-labeled 1j probe. <italic>Top</italic>, horizontal section depicting the dorsal tier of the brain; <italic>bottom</italic>, high magnification of coronal section depicting lobules of the cerebellum. The locations of the CA1/3 field of hippocampus proper (<italic>CA1/3</italic>), dentate gyrus (<italic>DG</italic>), medial habenula (<italic>MH</italic>), and the granular layer (<italic>GL</italic>) and molecular layer (<italic>ML</italic>) of the cerebellum are indicated. <italic>Scale bars</italic>, 2 mm (<italic>top</italic>) and 200 &#956;m (<italic>bottom</italic>). <italic>D</italic>, HEK293 cells expressing Myc-tagged GABA<sub>B1a</sub> (<italic>myc-1a</italic>) or GABA<sub>B1j</sub> (<italic>myc-1j</italic>) proteins. Conditioned medium (<italic>cond. med.</italic>) was subjected to immunoprecipitation with a rabbit anti-Myc antibody and analyzed in parallel with total cell lysate on Western blots using a mouse anti-Myc antibody. Membrane-bound GABA<sub>B1a</sub> protein was selectively detected in the cell lysate, whereas secreted GABA<sub>B1j</sub> protein was additionally detected in the cell-conditioned medium. <italic>E, left panel</italic>, the anti-SD monoclonal antibody 43H12 immunoprecipitates GABA<sub>B1a</sub> but not GABA<sub>B1b</sub> from mouse brain lysates. Immunoprecipitated GABA<sub>B1</sub> protein (<italic>IP anti-SD</italic>) was analyzed in parallel with total brain lysate (<italic>input</italic>) on Western blots using a pan GABA<sub>B1</sub> antibody (<xref ref-type="bibr" rid="ref12">12</xref>). <italic>Right panel</italic>, the anti-SD monoclonal antibody 43H12 immunoprecipitates two proteins with a molecular mass corresponding to that of GABA<sub>B1a</sub> (<sup>**</sup>) and GABA<sub>B1j</sub> (<sup>*</sup>) from metabolically labeled cortical neurons. Radiolabeled proteins were revealed by autoradiography.</p>
###xml 9 2312 9 2275 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="19"><bold>Characterization of the GABA<sub>B1j</sub> isoform.</bold><italic>A</italic>, schematic representation of the 5&#8242; end of the <italic>GABA<sub>B1</sub></italic> gene indicating the exons encoding the GABA<sub>B1a</sub>, GABA<sub>B1b</sub>, and GABA<sub>B1j</sub> isoforms. GABA<sub>B1j</sub> results from an 870-bp extension of exon 4 at its 3&#8242; end (exon 4&#8242;), generating an open reading frame of 687 nucleotides encompassing the two SDs. <italic>B</italic>, Northern blot analysis of GABA<sub>B1a</sub> and GABA<sub>B1j</sub> transcripts. Total RNA extracted from primary mouse cortical (<italic>ctx</italic>) neurons in culture or mouse brain was hybridized to the <sup>32</sup>P-labeled probes indicated in <italic>A</italic>. The pan probe encodes part of the extracellular GABA binding domain and detects &#8764;4.5-kb GABA<sub>B1a</sub> and &#8764;4.1-kb GABA<sub>B1b</sub> transcripts (not resolved). The SD1/2 probe encodes the two SDs and detects GABA<sub>B1a</sub> and &#8764;1.6-kb GABA<sub>B1j</sub> transcripts. The 1j probe encodes 510 nucleotides at the 3&#8242; end of exon 4&#8242;. <italic>C, in situ</italic> hybridization with the digoxigenin-labeled 1j probe. <italic>Top</italic>, horizontal section depicting the dorsal tier of the brain; <italic>bottom</italic>, high magnification of coronal section depicting lobules of the cerebellum. The locations of the CA1/3 field of hippocampus proper (<italic>CA1/3</italic>), dentate gyrus (<italic>DG</italic>), medial habenula (<italic>MH</italic>), and the granular layer (<italic>GL</italic>) and molecular layer (<italic>ML</italic>) of the cerebellum are indicated. <italic>Scale bars</italic>, 2 mm (<italic>top</italic>) and 200 &#956;m (<italic>bottom</italic>). <italic>D</italic>, HEK293 cells expressing Myc-tagged GABA<sub>B1a</sub> (<italic>myc-1a</italic>) or GABA<sub>B1j</sub> (<italic>myc-1j</italic>) proteins. Conditioned medium (<italic>cond. med.</italic>) was subjected to immunoprecipitation with a rabbit anti-Myc antibody and analyzed in parallel with total cell lysate on Western blots using a mouse anti-Myc antibody. Membrane-bound GABA<sub>B1a</sub> protein was selectively detected in the cell lysate, whereas secreted GABA<sub>B1j</sub> protein was additionally detected in the cell-conditioned medium. <italic>E, left panel</italic>, the anti-SD monoclonal antibody 43H12 immunoprecipitates GABA<sub>B1a</sub> but not GABA<sub>B1b</sub> from mouse brain lysates. Immunoprecipitated GABA<sub>B1</sub> protein (<italic>IP anti-SD</italic>) was analyzed in parallel with total brain lysate (<italic>input</italic>) on Western blots using a pan GABA<sub>B1</sub> antibody (<xref ref-type="bibr" rid="ref12">12</xref>). <italic>Right panel</italic>, the anti-SD monoclonal antibody 43H12 immunoprecipitates two proteins with a molecular mass corresponding to that of GABA<sub>B1a</sub> (<sup>**</sup>) and GABA<sub>B1j</sub> (<sup>*</sup>) from metabolically labeled cortical neurons. Radiolabeled proteins were revealed by autoradiography.</p></caption>
###xml 2312 2312 2275 2275 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0470855220001"/>
###xml 0 2312 0 2275 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="19"><bold>Characterization of the GABA<sub>B1j</sub> isoform.</bold><italic>A</italic>, schematic representation of the 5&#8242; end of the <italic>GABA<sub>B1</sub></italic> gene indicating the exons encoding the GABA<sub>B1a</sub>, GABA<sub>B1b</sub>, and GABA<sub>B1j</sub> isoforms. GABA<sub>B1j</sub> results from an 870-bp extension of exon 4 at its 3&#8242; end (exon 4&#8242;), generating an open reading frame of 687 nucleotides encompassing the two SDs. <italic>B</italic>, Northern blot analysis of GABA<sub>B1a</sub> and GABA<sub>B1j</sub> transcripts. Total RNA extracted from primary mouse cortical (<italic>ctx</italic>) neurons in culture or mouse brain was hybridized to the <sup>32</sup>P-labeled probes indicated in <italic>A</italic>. The pan probe encodes part of the extracellular GABA binding domain and detects &#8764;4.5-kb GABA<sub>B1a</sub> and &#8764;4.1-kb GABA<sub>B1b</sub> transcripts (not resolved). The SD1/2 probe encodes the two SDs and detects GABA<sub>B1a</sub> and &#8764;1.6-kb GABA<sub>B1j</sub> transcripts. The 1j probe encodes 510 nucleotides at the 3&#8242; end of exon 4&#8242;. <italic>C, in situ</italic> hybridization with the digoxigenin-labeled 1j probe. <italic>Top</italic>, horizontal section depicting the dorsal tier of the brain; <italic>bottom</italic>, high magnification of coronal section depicting lobules of the cerebellum. The locations of the CA1/3 field of hippocampus proper (<italic>CA1/3</italic>), dentate gyrus (<italic>DG</italic>), medial habenula (<italic>MH</italic>), and the granular layer (<italic>GL</italic>) and molecular layer (<italic>ML</italic>) of the cerebellum are indicated. <italic>Scale bars</italic>, 2 mm (<italic>top</italic>) and 200 &#956;m (<italic>bottom</italic>). <italic>D</italic>, HEK293 cells expressing Myc-tagged GABA<sub>B1a</sub> (<italic>myc-1a</italic>) or GABA<sub>B1j</sub> (<italic>myc-1j</italic>) proteins. Conditioned medium (<italic>cond. med.</italic>) was subjected to immunoprecipitation with a rabbit anti-Myc antibody and analyzed in parallel with total cell lysate on Western blots using a mouse anti-Myc antibody. Membrane-bound GABA<sub>B1a</sub> protein was selectively detected in the cell lysate, whereas secreted GABA<sub>B1j</sub> protein was additionally detected in the cell-conditioned medium. <italic>E, left panel</italic>, the anti-SD monoclonal antibody 43H12 immunoprecipitates GABA<sub>B1a</sub> but not GABA<sub>B1b</sub> from mouse brain lysates. Immunoprecipitated GABA<sub>B1</sub> protein (<italic>IP anti-SD</italic>) was analyzed in parallel with total brain lysate (<italic>input</italic>) on Western blots using a pan GABA<sub>B1</sub> antibody (<xref ref-type="bibr" rid="ref12">12</xref>). <italic>Right panel</italic>, the anti-SD monoclonal antibody 43H12 immunoprecipitates two proteins with a molecular mass corresponding to that of GABA<sub>B1a</sub> (<sup>**</sup>) and GABA<sub>B1j</sub> (<sup>*</sup>) from metabolically labeled cortical neurons. Radiolabeled proteins were revealed by autoradiography.</p></caption><graphic xlink:href="zbc0470855220001"/></fig>
###xml 433 438 <span type="species:ncbi:10090">mouse</span>
###xml 476 481 <span type="species:ncbi:10090">mouse</span>
###xml 1486 1492 <span type="species:ncbi:9986">rabbit</span>
###xml 1584 1589 <span type="species:ncbi:10090">mouse</span>
###xml 1877 1882 <span type="species:ncbi:10090">mouse</span>
FIGURE 1.Characterization of the GABAB1j isoform.A, schematic representation of the 5' end of the GABAB1 gene indicating the exons encoding the GABAB1a, GABAB1b, and GABAB1j isoforms. GABAB1j results from an 870-bp extension of exon 4 at its 3' end (exon 4'), generating an open reading frame of 687 nucleotides encompassing the two SDs. B, Northern blot analysis of GABAB1a and GABAB1j transcripts. Total RNA extracted from primary mouse cortical (ctx) neurons in culture or mouse brain was hybridized to the 32P-labeled probes indicated in A. The pan probe encodes part of the extracellular GABA binding domain and detects approximately4.5-kb GABAB1a and approximately4.1-kb GABAB1b transcripts (not resolved). The SD1/2 probe encodes the two SDs and detects GABAB1a and approximately1.6-kb GABAB1j transcripts. The 1j probe encodes 510 nucleotides at the 3' end of exon 4'. C, in situ hybridization with the digoxigenin-labeled 1j probe. Top, horizontal section depicting the dorsal tier of the brain; bottom, high magnification of coronal section depicting lobules of the cerebellum. The locations of the CA1/3 field of hippocampus proper (CA1/3), dentate gyrus (DG), medial habenula (MH), and the granular layer (GL) and molecular layer (ML) of the cerebellum are indicated. Scale bars, 2 mm (top) and 200 mum (bottom). D, HEK293 cells expressing Myc-tagged GABAB1a (myc-1a) or GABAB1j (myc-1j) proteins. Conditioned medium (cond. med.) was subjected to immunoprecipitation with a rabbit anti-Myc antibody and analyzed in parallel with total cell lysate on Western blots using a mouse anti-Myc antibody. Membrane-bound GABAB1a protein was selectively detected in the cell lysate, whereas secreted GABAB1j protein was additionally detected in the cell-conditioned medium. E, left panel, the anti-SD monoclonal antibody 43H12 immunoprecipitates GABAB1a but not GABAB1b from mouse brain lysates. Immunoprecipitated GABAB1 protein (IP anti-SD) was analyzed in parallel with total brain lysate (input) on Western blots using a pan GABAB1 antibody (12). Right panel, the anti-SD monoclonal antibody 43H12 immunoprecipitates two proteins with a molecular mass corresponding to that of GABAB1a (**) and GABAB1j (*) from metabolically labeled cortical neurons. Radiolabeled proteins were revealed by autoradiography.
###end p 18
###begin p 19
###xml 28 31 28 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of the GABA<sub>B1j</sub> isoform.</bold>
###xml 40 41 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 93 95 93 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GABA<sub>B1</sub></italic>
###xml 139 142 139 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 148 151 148 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 161 164 161 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 179 182 179 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 329 330 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 362 365 362 365 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 374 377 374 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 440 443 440 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ctx</italic>
###xml 501 503 501 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 533 534 533 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 640 643 628 631 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 672 675 648 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 756 759 732 735 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 788 791 752 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 868 878 832 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C, in situ</italic>
###xml 932 935 896 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Top</italic>
###xml 996 1002 960 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 1135 1140 1099 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CA1/3</italic>
###xml 1158 1160 1122 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DG</italic>
###xml 1180 1182 1144 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MH</italic>
###xml 1209 1211 1173 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GL</italic>
###xml 1234 1236 1198 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ML</italic>
###xml 1271 1281 1235 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bars</italic>
###xml 1289 1292 1253 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 1307 1313 1270 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 1316 1317 1279 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1358 1361 1321 1324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1363 1369 1326 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc-1a</italic>
###xml 1378 1381 1341 1344 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1383 1389 1346 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc-1j</italic>
###xml 1421 1431 1384 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cond. med.</italic>
###xml 1619 1622 1582 1585 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1697 1700 1660 1663 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1767 1780 1730 1743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E, left panel</italic>
###xml 1843 1846 1806 1809 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1859 1862 1822 1825 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 1912 1914 1875 1877 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 1924 1934 1887 1897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IP anti-SD</italic>
###xml 1986 1991 1949 1954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">input</italic>
###xml 2026 2028 1989 1991 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 2039 2041 2002 2004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 2044 2055 2007 2018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 2178 2181 2141 2144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 2183 2185 2146 2148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">**</sup>
###xml 2195 2198 2158 2161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 2200 2201 2163 2164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 424 429 <span type="species:ncbi:10090">mouse</span>
###xml 467 472 <span type="species:ncbi:10090">mouse</span>
###xml 1477 1483 <span type="species:ncbi:9986">rabbit</span>
###xml 1575 1580 <span type="species:ncbi:10090">mouse</span>
###xml 1868 1873 <span type="species:ncbi:10090">mouse</span>
Characterization of the GABAB1j isoform.A, schematic representation of the 5' end of the GABAB1 gene indicating the exons encoding the GABAB1a, GABAB1b, and GABAB1j isoforms. GABAB1j results from an 870-bp extension of exon 4 at its 3' end (exon 4'), generating an open reading frame of 687 nucleotides encompassing the two SDs. B, Northern blot analysis of GABAB1a and GABAB1j transcripts. Total RNA extracted from primary mouse cortical (ctx) neurons in culture or mouse brain was hybridized to the 32P-labeled probes indicated in A. The pan probe encodes part of the extracellular GABA binding domain and detects approximately4.5-kb GABAB1a and approximately4.1-kb GABAB1b transcripts (not resolved). The SD1/2 probe encodes the two SDs and detects GABAB1a and approximately1.6-kb GABAB1j transcripts. The 1j probe encodes 510 nucleotides at the 3' end of exon 4'. C, in situ hybridization with the digoxigenin-labeled 1j probe. Top, horizontal section depicting the dorsal tier of the brain; bottom, high magnification of coronal section depicting lobules of the cerebellum. The locations of the CA1/3 field of hippocampus proper (CA1/3), dentate gyrus (DG), medial habenula (MH), and the granular layer (GL) and molecular layer (ML) of the cerebellum are indicated. Scale bars, 2 mm (top) and 200 mum (bottom). D, HEK293 cells expressing Myc-tagged GABAB1a (myc-1a) or GABAB1j (myc-1j) proteins. Conditioned medium (cond. med.) was subjected to immunoprecipitation with a rabbit anti-Myc antibody and analyzed in parallel with total cell lysate on Western blots using a mouse anti-Myc antibody. Membrane-bound GABAB1a protein was selectively detected in the cell lysate, whereas secreted GABAB1j protein was additionally detected in the cell-conditioned medium. E, left panel, the anti-SD monoclonal antibody 43H12 immunoprecipitates GABAB1a but not GABAB1b from mouse brain lysates. Immunoprecipitated GABAB1 protein (IP anti-SD) was analyzed in parallel with total brain lysate (input) on Western blots using a pan GABAB1 antibody (12). Right panel, the anti-SD monoclonal antibody 43H12 immunoprecipitates two proteins with a molecular mass corresponding to that of GABAB1a (**) and GABAB1j (*) from metabolically labeled cortical neurons. Radiolabeled proteins were revealed by autoradiography.
###end p 19
###begin title 20
RESULTS
###end title 20
###begin p 21
###xml 4 7 4 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 0 39 0 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GABA<sub>B1j</sub> Encodes a Secreted Glycoprotein</italic>
###xml 56 58 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 238 241 226 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 247 250 235 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 269 272 257 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 342 343 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 336 343 324 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 367 368 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 409 412 397 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 434 437 422 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 606 609 594 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 698 699 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 692 699 668 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 759 762 735 738 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 771 774 747 750 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 819 820 795 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 813 820 789 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 831 834 807 810 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 884 885 860 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 878 885 854 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 924 927 900 903 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 929 931 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 976 979 952 955 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1036 1037 1012 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1133 1136 1109 1112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1196 1197 1160 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1190 1197 1154 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 1223 1226 1187 1190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1240 1241 1204 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1448 1451 1400 1403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1479 1482 1431 1434 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1551 1554 1503 1506 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1584 1585 1536 1537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1578 1585 1530 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 1641 1644 1593 1596 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1718 1721 1670 1673 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 1822 1825 1774 1777 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1859 1860 1811 1812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1853 1860 1805 1812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 1862 1872 1814 1824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left panel</italic>
###xml 1981 1984 1933 1936 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 2036 2037 1988 1989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 2030 2037 1982 1989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 2039 2050 1991 2002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right panel</italic>
###xml 2086 2089 2038 2041 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 2166 2169 2118 2121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 2178 2185 2130 2137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 83 86 <span type="species:ncbi:10116">rat</span>
GABAB1j Encodes a Secreted Glycoprotein-To identify GABAB1 isoforms, we screened a rat cortex/cerebellum cDNA library with an SD-specific hybridization probe. We isolated cDNAs for a novel isoform of approximately1.6 kb that we named GABAB1j. GABAB1j diverges from GABAB1a downstream of exon 4 and encodes a protein of 229 amino acids (Fig. 1A and supplemental Fig. 1A). The N-terminal 157 amino acids of GABAB1j are identical to GABAB1a and encode the signal peptide as well as the two SDs; the C-terminal 72 residues exhibit no significant homology to known proteins. Northern blot analysis revealed GABAB1j transcripts of approximately1.6 kb in brain tissue and cultured cortical neurons (Fig. 1B). An SD-specific hybridization probe demonstrated that GABAB1j and GABAB1a transcripts are of similar abundance (Fig. 1B). The GABAB1j transcript distribution in brain sections (Fig. 1C) is similar to that described for GABAB1a (32). Hydropathicity analysis revealed that GABAB1j protein lacks transmembrane domains (supplemental Fig. 1B). Western blot analysis of transiently transfected HEK293 cells showed that the Myc-tagged GABAB1j protein has a molecular mass of approximately29 kDa (Fig. 1D). Deglycosylation of GABAB1j with peptide N-glycosidase F decreased the molecular mass to approximately23 kDa (data not shown), which corresponds to the calculated molecular weight of the mature protein. Immunoprecipitation experiments recovered GABAB1j but not membrane-bound GABAB1a from conditioned HEK293 cell-culture medium, demonstrating that GABAB1j is a secreted protein (Fig. 1D). We next addressed whether endogenously expressed GABAB1j protein is detectable in neurons. We did not succeed in generating a GABAB1j-specific antibody; however, we generated an anti-SD monoclonal antibody that immunoprecipitates GABAB1a protein from brain tissue (Fig. 1E, left panel). In addition, the antibody immunoprecipitates a protein with a molecular mass corresponding to that of GABAB1j from metabolically labeled cortical neurons (Fig. 1E, right panel). In the absence of a specific GABAB1j antibody, this provides indirect evidence for the existence of a stable GABAB1j protein in vivo.
###end p 21
###begin p 22
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 36 39 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 9 83 9 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Specific binding sites for <sup>125</sup>I-Tyr-RSDP in rat cortex synaptic membranes.</bold>
###xml 83 84 83 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 108 128 108 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pichia pastoris. Top</italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEVcs</italic>
###xml 288 290 288 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">x6</sub>
###xml 288 290 288 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sub>x6</sub></italic>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bottom</italic>
###xml 368 369 368 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 526 527 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 543 550 519 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PNGaseF</italic>
###xml 631 632 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 634 637 604 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 654 655 624 625 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 764 765 733 734 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 850 851 817 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 867 870 834 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 887 888 854 855 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 9 1107 9 1071 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23"><bold>Specific binding sites for <sup>125</sup>I-Tyr-RSDP in rat cortex synaptic membranes.</bold><italic>A</italic>, expression of RSDP in <italic>Pichia pastoris. Top</italic>, a schematic representation of RSDP containing the two SDs flanked by two tobacco etch virus cleavage sites (<italic>TEVcs</italic>) and C-terminal c-Myc and polyhistidine (His<italic><sub>x6</sub></italic>) tags. <italic>Bottom</italic>, recombinant protein identified on Western blots using anti-His<sub>6</sub> antibodies. RSDP is <italic>N</italic>-glycosylated as indicated by the shift from &#8764;29 kDa to the calculated molecular mass of &#8764;23 kDa after peptide <italic>N</italic>-glycosidase F (<italic>PNGaseF</italic>) treatment. RSDP is stable at 37 &#176;C for at least 7 days (data not shown). <italic>B</italic>, <sup>125</sup>I-Tyr-RSDP (0.5 n<sc>m</sc>) binding to 20 &#956;g of membranes from cortex, CHO-K1, and HEK293FT cells, in the absence or presence of 200 n<sc>m</sc> unlabeled RSDP protein. Data are means &#177; S.D. from three independent experiments. <italic>C</italic>, inhibition of <sup>125</sup>I-Tyr-RSDP (0.5 n<sc>m</sc>) binding to 40 &#956;g of cortical membranes by different concentrations of unlabeled RSDP. The inhibition curve was calculated using nonlinear regression. Data points are means &#177; S.E. from three independent experiments.</p>
###xml 9 1107 9 1071 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23"><bold>Specific binding sites for <sup>125</sup>I-Tyr-RSDP in rat cortex synaptic membranes.</bold><italic>A</italic>, expression of RSDP in <italic>Pichia pastoris. Top</italic>, a schematic representation of RSDP containing the two SDs flanked by two tobacco etch virus cleavage sites (<italic>TEVcs</italic>) and C-terminal c-Myc and polyhistidine (His<italic><sub>x6</sub></italic>) tags. <italic>Bottom</italic>, recombinant protein identified on Western blots using anti-His<sub>6</sub> antibodies. RSDP is <italic>N</italic>-glycosylated as indicated by the shift from &#8764;29 kDa to the calculated molecular mass of &#8764;23 kDa after peptide <italic>N</italic>-glycosidase F (<italic>PNGaseF</italic>) treatment. RSDP is stable at 37 &#176;C for at least 7 days (data not shown). <italic>B</italic>, <sup>125</sup>I-Tyr-RSDP (0.5 n<sc>m</sc>) binding to 20 &#956;g of membranes from cortex, CHO-K1, and HEK293FT cells, in the absence or presence of 200 n<sc>m</sc> unlabeled RSDP protein. Data are means &#177; S.D. from three independent experiments. <italic>C</italic>, inhibition of <sup>125</sup>I-Tyr-RSDP (0.5 n<sc>m</sc>) binding to 40 &#956;g of cortical membranes by different concentrations of unlabeled RSDP. The inhibition curve was calculated using nonlinear regression. Data points are means &#177; S.E. from three independent experiments.</p></caption>
###xml 1107 1107 1071 1071 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0470855220002"/>
###xml 0 1107 0 1071 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="23"><bold>Specific binding sites for <sup>125</sup>I-Tyr-RSDP in rat cortex synaptic membranes.</bold><italic>A</italic>, expression of RSDP in <italic>Pichia pastoris. Top</italic>, a schematic representation of RSDP containing the two SDs flanked by two tobacco etch virus cleavage sites (<italic>TEVcs</italic>) and C-terminal c-Myc and polyhistidine (His<italic><sub>x6</sub></italic>) tags. <italic>Bottom</italic>, recombinant protein identified on Western blots using anti-His<sub>6</sub> antibodies. RSDP is <italic>N</italic>-glycosylated as indicated by the shift from &#8764;29 kDa to the calculated molecular mass of &#8764;23 kDa after peptide <italic>N</italic>-glycosidase F (<italic>PNGaseF</italic>) treatment. RSDP is stable at 37 &#176;C for at least 7 days (data not shown). <italic>B</italic>, <sup>125</sup>I-Tyr-RSDP (0.5 n<sc>m</sc>) binding to 20 &#956;g of membranes from cortex, CHO-K1, and HEK293FT cells, in the absence or presence of 200 n<sc>m</sc> unlabeled RSDP protein. Data are means &#177; S.D. from three independent experiments. <italic>C</italic>, inhibition of <sup>125</sup>I-Tyr-RSDP (0.5 n<sc>m</sc>) binding to 40 &#956;g of cortical membranes by different concentrations of unlabeled RSDP. The inhibition curve was calculated using nonlinear regression. Data points are means &#177; S.E. from three independent experiments.</p></caption><graphic xlink:href="zbc0470855220002"/></fig>
###xml 53 56 <span type="species:ncbi:10116">rat</span>
###xml 108 123 <span type="species:ncbi:4922">Pichia pastoris</span>
###xml 203 221 <span type="species:ncbi:12227">tobacco etch virus</span>
FIGURE 2.Specific binding sites for 125I-Tyr-RSDP in rat cortex synaptic membranes.A, expression of RSDP in Pichia pastoris. Top, a schematic representation of RSDP containing the two SDs flanked by two tobacco etch virus cleavage sites (TEVcs) and C-terminal c-Myc and polyhistidine (Hisx6) tags. Bottom, recombinant protein identified on Western blots using anti-His6 antibodies. RSDP is N-glycosylated as indicated by the shift from approximately29 kDa to the calculated molecular mass of approximately23 kDa after peptide N-glycosidase F (PNGaseF) treatment. RSDP is stable at 37 degreesC for at least 7 days (data not shown). B, 125I-Tyr-RSDP (0.5 nm) binding to 20 mug of membranes from cortex, CHO-K1, and HEK293FT cells, in the absence or presence of 200 nm unlabeled RSDP protein. Data are means +/- S.D. from three independent experiments. C, inhibition of 125I-Tyr-RSDP (0.5 nm) binding to 40 mug of cortical membranes by different concentrations of unlabeled RSDP. The inhibition curve was calculated using nonlinear regression. Data points are means +/- S.E. from three independent experiments.
###end p 22
###begin p 23
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Specific binding sites for <sup>125</sup>I-Tyr-RSDP in rat cortex synaptic membranes.</bold>
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 99 119 99 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pichia pastoris. Top</italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEVcs</italic>
###xml 279 281 279 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink">x6</sub>
###xml 279 281 279 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sub>x6</sub></italic>
###xml 289 295 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bottom</italic>
###xml 359 360 359 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 517 518 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 534 541 510 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PNGaseF</italic>
###xml 622 623 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 625 628 595 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 645 646 615 616 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 755 756 724 725 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 841 842 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 858 861 825 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 878 879 845 846 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 44 47 <span type="species:ncbi:10116">rat</span>
###xml 99 114 <span type="species:ncbi:4922">Pichia pastoris</span>
###xml 194 212 <span type="species:ncbi:12227">tobacco etch virus</span>
Specific binding sites for 125I-Tyr-RSDP in rat cortex synaptic membranes.A, expression of RSDP in Pichia pastoris. Top, a schematic representation of RSDP containing the two SDs flanked by two tobacco etch virus cleavage sites (TEVcs) and C-terminal c-Myc and polyhistidine (Hisx6) tags. Bottom, recombinant protein identified on Western blots using anti-His6 antibodies. RSDP is N-glycosylated as indicated by the shift from approximately29 kDa to the calculated molecular mass of approximately23 kDa after peptide N-glycosidase F (PNGaseF) treatment. RSDP is stable at 37 degreesC for at least 7 days (data not shown). B, 125I-Tyr-RSDP (0.5 nm) binding to 20 mug of membranes from cortex, CHO-K1, and HEK293FT cells, in the absence or presence of 200 nm unlabeled RSDP protein. Data are means +/- S.D. from three independent experiments. C, inhibition of 125I-Tyr-RSDP (0.5 nm) binding to 40 mug of cortical membranes by different concentrations of unlabeled RSDP. The inhibition curve was calculated using nonlinear regression. Data points are means +/- S.E. from three independent experiments.
###end p 23
###begin p 24
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 9 136 9 136 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RSDP impairs GABA<sub>B</sub> receptor-mediated inhibition of spontaneous glutamate release in dissociated hippocampal neurons in culture.</bold>
###xml 136 137 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 210 211 209 210 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 279 280 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 315 316 314 315 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 318 319 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 332 333 331 332 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 335 336 334 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 412 413 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 520 521 519 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 542 543 541 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 602 603 601 602 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 635 638 634 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bac</italic>
###xml 659 664 658 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">adeno</italic>
###xml 791 792 787 788 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 823 824 817 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 851 852 843 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 858 861 850 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 863 864 855 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 900 901 891 892 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 934 935 923 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 962 963 949 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 970 971 957 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1087 1091 1074 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wash</italic>
###xml 1150 1151 1137 1138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 9 1245 9 1232 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25"><bold>RSDP impairs GABA<sub>B</sub> receptor-mediated inhibition of spontaneous glutamate release in dissociated hippocampal neurons in culture.</bold><italic>A</italic>, the percentage of inhibition of the mEPSC frequency by baclofen (100 &#956;<sc>m</sc>) was assessed in individual neurons under control condition (ACSF, <italic>n</italic> = 5) and after incubation with 4 n<sc>m</sc> (<italic>n</italic> = 5) or 40 n<sc>m</sc> (<italic>n</italic> = 7) RSDP for the times indicated (for values, see supplemental Table S1). <italic>B</italic>, time course of the RSDP effect on the baclofen-induced mEPSC frequency inhibition in individual neurons (<italic>n</italic> = 5 per condition). <italic>C</italic>, summary histograms illustrating that incubation with 40 n<sc>m</sc> RSDP for 1 h impairs baclofen (<italic>bac</italic>)-but not adenosine (<italic>adeno</italic>)-mediated mEPSC frequency inhibition. Values are means &#177; S.E. of the percentage of inhibition of the mEPSC frequency (100 &#956;<sc>m</sc> baclofen, ACSF, 88.6 &#177; 2.4% <italic>n</italic> = 5; RSDP, 15.7 &#177; 3.2%, <italic>n</italic> = 5, <sup>***</sup>, <italic>p</italic> &lt; 0.001, Kolmogorov-Smirnov; 100 &#956;<sc>m</sc> adenosine, ACSF, 70.2 &#177; 4.0%, <italic>n</italic> = 5; RSDP, 78.6 &#177; 2.7%, <italic>n</italic> = 5). <italic>D</italic>, representative mEPSC recordings under baseline conditions, during adenosine application, after washing with ACSF (<italic>wash</italic>), during baclofen application, and after antagonizing GABA<sub>B</sub> receptors with CGP54626. Recordings from one cell each incubated with ACSF or RSDP are shown.</p>
###xml 9 1245 9 1232 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25"><bold>RSDP impairs GABA<sub>B</sub> receptor-mediated inhibition of spontaneous glutamate release in dissociated hippocampal neurons in culture.</bold><italic>A</italic>, the percentage of inhibition of the mEPSC frequency by baclofen (100 &#956;<sc>m</sc>) was assessed in individual neurons under control condition (ACSF, <italic>n</italic> = 5) and after incubation with 4 n<sc>m</sc> (<italic>n</italic> = 5) or 40 n<sc>m</sc> (<italic>n</italic> = 7) RSDP for the times indicated (for values, see supplemental Table S1). <italic>B</italic>, time course of the RSDP effect on the baclofen-induced mEPSC frequency inhibition in individual neurons (<italic>n</italic> = 5 per condition). <italic>C</italic>, summary histograms illustrating that incubation with 40 n<sc>m</sc> RSDP for 1 h impairs baclofen (<italic>bac</italic>)-but not adenosine (<italic>adeno</italic>)-mediated mEPSC frequency inhibition. Values are means &#177; S.E. of the percentage of inhibition of the mEPSC frequency (100 &#956;<sc>m</sc> baclofen, ACSF, 88.6 &#177; 2.4% <italic>n</italic> = 5; RSDP, 15.7 &#177; 3.2%, <italic>n</italic> = 5, <sup>***</sup>, <italic>p</italic> &lt; 0.001, Kolmogorov-Smirnov; 100 &#956;<sc>m</sc> adenosine, ACSF, 70.2 &#177; 4.0%, <italic>n</italic> = 5; RSDP, 78.6 &#177; 2.7%, <italic>n</italic> = 5). <italic>D</italic>, representative mEPSC recordings under baseline conditions, during adenosine application, after washing with ACSF (<italic>wash</italic>), during baclofen application, and after antagonizing GABA<sub>B</sub> receptors with CGP54626. Recordings from one cell each incubated with ACSF or RSDP are shown.</p></caption>
###xml 1245 1245 1232 1232 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0470855220003"/>
###xml 0 1245 0 1232 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="25"><bold>RSDP impairs GABA<sub>B</sub> receptor-mediated inhibition of spontaneous glutamate release in dissociated hippocampal neurons in culture.</bold><italic>A</italic>, the percentage of inhibition of the mEPSC frequency by baclofen (100 &#956;<sc>m</sc>) was assessed in individual neurons under control condition (ACSF, <italic>n</italic> = 5) and after incubation with 4 n<sc>m</sc> (<italic>n</italic> = 5) or 40 n<sc>m</sc> (<italic>n</italic> = 7) RSDP for the times indicated (for values, see supplemental Table S1). <italic>B</italic>, time course of the RSDP effect on the baclofen-induced mEPSC frequency inhibition in individual neurons (<italic>n</italic> = 5 per condition). <italic>C</italic>, summary histograms illustrating that incubation with 40 n<sc>m</sc> RSDP for 1 h impairs baclofen (<italic>bac</italic>)-but not adenosine (<italic>adeno</italic>)-mediated mEPSC frequency inhibition. Values are means &#177; S.E. of the percentage of inhibition of the mEPSC frequency (100 &#956;<sc>m</sc> baclofen, ACSF, 88.6 &#177; 2.4% <italic>n</italic> = 5; RSDP, 15.7 &#177; 3.2%, <italic>n</italic> = 5, <sup>***</sup>, <italic>p</italic> &lt; 0.001, Kolmogorov-Smirnov; 100 &#956;<sc>m</sc> adenosine, ACSF, 70.2 &#177; 4.0%, <italic>n</italic> = 5; RSDP, 78.6 &#177; 2.7%, <italic>n</italic> = 5). <italic>D</italic>, representative mEPSC recordings under baseline conditions, during adenosine application, after washing with ACSF (<italic>wash</italic>), during baclofen application, and after antagonizing GABA<sub>B</sub> receptors with CGP54626. Recordings from one cell each incubated with ACSF or RSDP are shown.</p></caption><graphic xlink:href="zbc0470855220003"/></fig>
FIGURE 3.RSDP impairs GABAB receptor-mediated inhibition of spontaneous glutamate release in dissociated hippocampal neurons in culture.A, the percentage of inhibition of the mEPSC frequency by baclofen (100 mum) was assessed in individual neurons under control condition (ACSF, n = 5) and after incubation with 4 nm (n = 5) or 40 nm (n = 7) RSDP for the times indicated (for values, see supplemental Table S1). B, time course of the RSDP effect on the baclofen-induced mEPSC frequency inhibition in individual neurons (n = 5 per condition). C, summary histograms illustrating that incubation with 40 nm RSDP for 1 h impairs baclofen (bac)-but not adenosine (adeno)-mediated mEPSC frequency inhibition. Values are means +/- S.E. of the percentage of inhibition of the mEPSC frequency (100 mum baclofen, ACSF, 88.6 +/- 2.4% n = 5; RSDP, 15.7 +/- 3.2%, n = 5, ***, p < 0.001, Kolmogorov-Smirnov; 100 mum adenosine, ACSF, 70.2 +/- 4.0%, n = 5; RSDP, 78.6 +/- 2.7%, n = 5). D, representative mEPSC recordings under baseline conditions, during adenosine application, after washing with ACSF (wash), during baclofen application, and after antagonizing GABAB receptors with CGP54626. Recordings from one cell each incubated with ACSF or RSDP are shown.
###end p 24
###begin p 25
###xml 17 18 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 0 127 0 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RSDP impairs GABA<sub>B</sub> receptor-mediated inhibition of spontaneous glutamate release in dissociated hippocampal neurons in culture.</bold>
###xml 127 128 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 201 202 200 201 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 270 271 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 306 307 305 306 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 309 310 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 323 324 322 323 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 326 327 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 403 404 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 511 512 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 533 534 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 593 594 592 593 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 626 629 625 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bac</italic>
###xml 650 655 649 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">adeno</italic>
###xml 782 783 778 779 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 814 815 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 842 843 834 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 849 852 841 844 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 854 855 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 891 892 882 883 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 925 926 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 953 954 940 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 961 962 948 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1078 1082 1065 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">wash</italic>
###xml 1141 1142 1128 1129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
RSDP impairs GABAB receptor-mediated inhibition of spontaneous glutamate release in dissociated hippocampal neurons in culture.A, the percentage of inhibition of the mEPSC frequency by baclofen (100 mum) was assessed in individual neurons under control condition (ACSF, n = 5) and after incubation with 4 nm (n = 5) or 40 nm (n = 7) RSDP for the times indicated (for values, see supplemental Table S1). B, time course of the RSDP effect on the baclofen-induced mEPSC frequency inhibition in individual neurons (n = 5 per condition). C, summary histograms illustrating that incubation with 40 nm RSDP for 1 h impairs baclofen (bac)-but not adenosine (adeno)-mediated mEPSC frequency inhibition. Values are means +/- S.E. of the percentage of inhibition of the mEPSC frequency (100 mum baclofen, ACSF, 88.6 +/- 2.4% n = 5; RSDP, 15.7 +/- 3.2%, n = 5, ***, p < 0.001, Kolmogorov-Smirnov; 100 mum adenosine, ACSF, 70.2 +/- 4.0%, n = 5; RSDP, 78.6 +/- 2.7%, n = 5). D, representative mEPSC recordings under baseline conditions, during adenosine application, after washing with ACSF (wash), during baclofen application, and after antagonizing GABAB receptors with CGP54626. Recordings from one cell each incubated with ACSF or RSDP are shown.
###end p 25
###begin p 26
###xml 0 66 0 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neuronal Membranes Exhibit High Affinity Binding Sites for the SDs</italic>
###xml 178 181 178 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 253 260 253 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 295 298 295 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 392 395 392 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 497 498 497 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 491 498 491 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 513 516 513 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 609 610 609 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 603 610 603 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 681 684 681 684 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 722 723 710 711 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 743 744 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 783 784 771 772 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 792 793 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 786 793 774 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 415 418 <span type="species:ncbi:10116">rat</span>
Neuronal Membranes Exhibit High Affinity Binding Sites for the SDs-To address whether SDs interact with specific binding sites in neuronal membranes, we produced a truncated GABAB1j protein containing the two SDs but lacking the C-terminal 72 residues (Fig. 2A). This RSDP was radiolabeled with 125I at tyrosine residues and used in competition binding experiments. Approximately half of the 125I-Tyr-RSDP bound to rat cortex synaptic membranes was specifically displaced by unlabeled RSDP (Fig. 2B). No specific 125I-Tyr-RSDP binding sites were detected in cell membranes of HEK293FT and CHO-K1 cells (Fig. 2B). Concentration-response curves revealed a half-maximal inhibition of 125I-Tyr-RSDP binding at approximately2 nm of unlabeled RSDP (n = 3, 95% confidence interval 1.1-3.4 nm; Fig. 2C).
###end p 26
###begin p 27
###xml 17 18 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 0 80 0 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RSDP Impairs GABA<sub>B</sub> Receptor-mediated Inhibition of Spontaneous Glutamate Release</italic>
###xml 85 86 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 212 214 212 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 428 431 428 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 484 485 484 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 519 520 518 519 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 567 568 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 573 574 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 559 574 558 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>A</italic> and <italic>B</italic></xref>
###xml 710 711 709 710 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 768 769 767 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 762 769 761 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 779 780 778 779 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 960 961 959 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 966 967 965 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 952 967 951 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>A</italic> and <italic>B</italic></xref>
###xml 1153 1154 1152 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1159 1160 1158 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1145 1160 1144 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, <italic>C</italic> and <italic>D</italic></xref>
###xml 1207 1208 1206 1207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1220 1221 1219 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 1223 1225 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
RSDP Impairs GABAB Receptor-mediated Inhibition of Spontaneous Glutamate Release-GABAB heteroreceptors inhibit the spontaneous release of glutamate, likely by interfering with the release process downstream of Ca2+ entry (7, 8, 22). We addressed whether exogenous application of RSDP to dissociated hippocampal neurons in culture exerts a dominant-negative effect on heteroreceptors by scavenging a binding partner of their GABAB1a subunits. Under control conditions in ACSF, the GABAB receptor agonist baclofen (100 mum) significantly reduced the frequency (Fig. 3, A and B) but not the amplitude (data not shown) of mEPSCs recorded from pyramidal neurons, consistent with a presynaptic mode of action. At 4 nm of RSDP, a maximal impairment is seen after 12 h (Fig. 3A). At 40 nm of RSDP, a partial impairment of presynaptic inhibition was observed as early as 10 min after RSDP application, whereas a near complete impairment was observed after 1 h (Fig. 3, A and B). This shows that the effect of RSDP is concentration-dependent. RSDP did not interfere with the inhibition of spontaneous glutamate release mediated by adenosine A1 receptors (Fig. 3, C and D), which converge on the same effectors as GABAB receptors (7, 22). This demonstrates that RSDP does not indiscriminately act at presynaptic G-protein-coupled receptors.
###end p 27
###begin p 28
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 38 45 38 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 9 91 9 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RSDP selectively impairs GABA<sub>B(1a,2)</sub> receptors located at glutamatergic terminals.</bold>
###xml 91 92 91 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 162 165 162 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bac</italic>
###xml 173 174 172 173 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 191 196 190 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">adeno</italic>
###xml 204 205 202 203 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 238 248 236 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white bars</italic>
###xml 315 317 313 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 339 340 337 338 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 342 352 340 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 568 569 564 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 606 607 600 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 613 616 607 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 618 619 612 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 788 789 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 827 828 817 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1286 1287 1276 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1308 1309 1298 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1378 1381 1368 1371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1440 1441 1426 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1447 1450 1433 1436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 1452 1453 1438 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1718 1721 1704 1707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1771 1773 1757 1759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1776 1777 1762 1763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1832 1835 1818 1821 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1864 1865 1850 1851 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1897 1899 1883 1885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1933 1936 1919 1922 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 2021 2023 2007 2009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 2188 2191 2174 2177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 9 2227 9 2211 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29"><bold>RSDP selectively impairs GABA<sub>B(1a,2)</sub> receptors located at glutamatergic terminals.</bold><italic>A</italic>, the percentage of mEPSC and mIPSC frequency inhibition by baclofen (<italic>bac</italic>, 100 &#956;<sc>m</sc>) and adenosine (<italic>adeno</italic>, 100 &#956;<sc>m</sc>) under control condition (ACSF, <italic>white bars</italic>) and after incubation of acute hippocampal slices from wild-type (<italic>WT</italic>) mice with RSDP (40 n<sc>m</sc>, <italic>black bars</italic>) for 6 h. Baclofen was significantly less efficient in reducing the frequency of mEPSCs recorded from CA1 pyramidal neurons incubated with RSDP than from neurons incubated with ACSF (ACSF, 71.0 &#177; 5.4% inhibition, <italic>n</italic> = 5; RSDP, 7.6 &#177; 2.2% inhibition, <italic>n</italic> = 9; <sup>***</sup>, <italic>p</italic> &lt; 0.001, Kolmogorov-Smirnov; see also supplemental Table S2). RSDP was without effect on adenosine-mediated mEPSC frequency inhibition (ACSF, 67.0 &#177; 5.3% inhibition, <italic>n</italic> = 5; RSDP, 76.0 &#177; 3.0% inhibition, <italic>n</italic> = 9; supplemental Table S2). As an additional control, RSDP was also without effect on the baseline mEPSC frequency or amplitude (for values, see supplemental Table S3). RSDP did not affect the baclofen- or adenosinemediated inhibition of the mIPSCs frequency recorded from CA1 pyramidal neurons (for values, see supplemental Table S2). RSDP did not alter the amplitudes of Kir3 current responses induced by baclofen and adenosine in CA1 pyramidal neurons (<italic>n</italic> = 6 per condition). <italic>B</italic>, RSDP impairs the baclofen-mediated mEPSC frequency inhibition in 1b<sup>-/-</sup> mice (ACSF, 67.0 &#177; 3.0% inhibition; RSDP, 6.0 &#177; 2.0%; <italic>n</italic> = 4; <sup>***</sup>, <italic>p</italic> &lt; 0.001, Kolmogorov-Smirnov). Incubation with RSDP had no effect on baclofen- or adenosine-mediated effects on the mIPSC frequency (for values, see supplemental Table S2) or on Kir3 current amplitudes. Baclofen-induced Kir3 current responses were reduced in the 1b<sup>-/-</sup> when compared with wild-type mice, as described (<xref ref-type="bibr" rid="ref22">22</xref>). <italic>C</italic>, baclofen failed to depress the mEPSCs frequency in 1a<sup>-/-</sup> mice due to the lack of GABA<sub>B</sub> heteroreceptors in these mice (<xref ref-type="bibr" rid="ref22">22</xref>). The basal mEPSC frequency in 1a<sup>-/-</sup> mice was increased (for values, see supplemental Table S3), as reported previously (<xref ref-type="bibr" rid="ref22">22</xref>). RSDP was without effect on the baclofen- or adenosine-mediated inhibition of the mIPSC frequency (for values, see supplemental Table S2) or on Kir3 currents in 1a<sup>-/-</sup> mice. All values are means &#177; S.E.</p>
###xml 9 2227 9 2211 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29"><bold>RSDP selectively impairs GABA<sub>B(1a,2)</sub> receptors located at glutamatergic terminals.</bold><italic>A</italic>, the percentage of mEPSC and mIPSC frequency inhibition by baclofen (<italic>bac</italic>, 100 &#956;<sc>m</sc>) and adenosine (<italic>adeno</italic>, 100 &#956;<sc>m</sc>) under control condition (ACSF, <italic>white bars</italic>) and after incubation of acute hippocampal slices from wild-type (<italic>WT</italic>) mice with RSDP (40 n<sc>m</sc>, <italic>black bars</italic>) for 6 h. Baclofen was significantly less efficient in reducing the frequency of mEPSCs recorded from CA1 pyramidal neurons incubated with RSDP than from neurons incubated with ACSF (ACSF, 71.0 &#177; 5.4% inhibition, <italic>n</italic> = 5; RSDP, 7.6 &#177; 2.2% inhibition, <italic>n</italic> = 9; <sup>***</sup>, <italic>p</italic> &lt; 0.001, Kolmogorov-Smirnov; see also supplemental Table S2). RSDP was without effect on adenosine-mediated mEPSC frequency inhibition (ACSF, 67.0 &#177; 5.3% inhibition, <italic>n</italic> = 5; RSDP, 76.0 &#177; 3.0% inhibition, <italic>n</italic> = 9; supplemental Table S2). As an additional control, RSDP was also without effect on the baseline mEPSC frequency or amplitude (for values, see supplemental Table S3). RSDP did not affect the baclofen- or adenosinemediated inhibition of the mIPSCs frequency recorded from CA1 pyramidal neurons (for values, see supplemental Table S2). RSDP did not alter the amplitudes of Kir3 current responses induced by baclofen and adenosine in CA1 pyramidal neurons (<italic>n</italic> = 6 per condition). <italic>B</italic>, RSDP impairs the baclofen-mediated mEPSC frequency inhibition in 1b<sup>-/-</sup> mice (ACSF, 67.0 &#177; 3.0% inhibition; RSDP, 6.0 &#177; 2.0%; <italic>n</italic> = 4; <sup>***</sup>, <italic>p</italic> &lt; 0.001, Kolmogorov-Smirnov). Incubation with RSDP had no effect on baclofen- or adenosine-mediated effects on the mIPSC frequency (for values, see supplemental Table S2) or on Kir3 current amplitudes. Baclofen-induced Kir3 current responses were reduced in the 1b<sup>-/-</sup> when compared with wild-type mice, as described (<xref ref-type="bibr" rid="ref22">22</xref>). <italic>C</italic>, baclofen failed to depress the mEPSCs frequency in 1a<sup>-/-</sup> mice due to the lack of GABA<sub>B</sub> heteroreceptors in these mice (<xref ref-type="bibr" rid="ref22">22</xref>). The basal mEPSC frequency in 1a<sup>-/-</sup> mice was increased (for values, see supplemental Table S3), as reported previously (<xref ref-type="bibr" rid="ref22">22</xref>). RSDP was without effect on the baclofen- or adenosine-mediated inhibition of the mIPSC frequency (for values, see supplemental Table S2) or on Kir3 currents in 1a<sup>-/-</sup> mice. All values are means &#177; S.E.</p></caption>
###xml 2227 2227 2211 2211 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0470855220004"/>
###xml 0 2227 0 2211 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="29"><bold>RSDP selectively impairs GABA<sub>B(1a,2)</sub> receptors located at glutamatergic terminals.</bold><italic>A</italic>, the percentage of mEPSC and mIPSC frequency inhibition by baclofen (<italic>bac</italic>, 100 &#956;<sc>m</sc>) and adenosine (<italic>adeno</italic>, 100 &#956;<sc>m</sc>) under control condition (ACSF, <italic>white bars</italic>) and after incubation of acute hippocampal slices from wild-type (<italic>WT</italic>) mice with RSDP (40 n<sc>m</sc>, <italic>black bars</italic>) for 6 h. Baclofen was significantly less efficient in reducing the frequency of mEPSCs recorded from CA1 pyramidal neurons incubated with RSDP than from neurons incubated with ACSF (ACSF, 71.0 &#177; 5.4% inhibition, <italic>n</italic> = 5; RSDP, 7.6 &#177; 2.2% inhibition, <italic>n</italic> = 9; <sup>***</sup>, <italic>p</italic> &lt; 0.001, Kolmogorov-Smirnov; see also supplemental Table S2). RSDP was without effect on adenosine-mediated mEPSC frequency inhibition (ACSF, 67.0 &#177; 5.3% inhibition, <italic>n</italic> = 5; RSDP, 76.0 &#177; 3.0% inhibition, <italic>n</italic> = 9; supplemental Table S2). As an additional control, RSDP was also without effect on the baseline mEPSC frequency or amplitude (for values, see supplemental Table S3). RSDP did not affect the baclofen- or adenosinemediated inhibition of the mIPSCs frequency recorded from CA1 pyramidal neurons (for values, see supplemental Table S2). RSDP did not alter the amplitudes of Kir3 current responses induced by baclofen and adenosine in CA1 pyramidal neurons (<italic>n</italic> = 6 per condition). <italic>B</italic>, RSDP impairs the baclofen-mediated mEPSC frequency inhibition in 1b<sup>-/-</sup> mice (ACSF, 67.0 &#177; 3.0% inhibition; RSDP, 6.0 &#177; 2.0%; <italic>n</italic> = 4; <sup>***</sup>, <italic>p</italic> &lt; 0.001, Kolmogorov-Smirnov). Incubation with RSDP had no effect on baclofen- or adenosine-mediated effects on the mIPSC frequency (for values, see supplemental Table S2) or on Kir3 current amplitudes. Baclofen-induced Kir3 current responses were reduced in the 1b<sup>-/-</sup> when compared with wild-type mice, as described (<xref ref-type="bibr" rid="ref22">22</xref>). <italic>C</italic>, baclofen failed to depress the mEPSCs frequency in 1a<sup>-/-</sup> mice due to the lack of GABA<sub>B</sub> heteroreceptors in these mice (<xref ref-type="bibr" rid="ref22">22</xref>). The basal mEPSC frequency in 1a<sup>-/-</sup> mice was increased (for values, see supplemental Table S3), as reported previously (<xref ref-type="bibr" rid="ref22">22</xref>). RSDP was without effect on the baclofen- or adenosine-mediated inhibition of the mIPSC frequency (for values, see supplemental Table S2) or on Kir3 currents in 1a<sup>-/-</sup> mice. All values are means &#177; S.E.</p></caption><graphic xlink:href="zbc0470855220004"/></fig>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 1382 1386 <span type="species:ncbi:10090">mice</span>
###xml 1751 1755 <span type="species:ncbi:10090">mice</span>
###xml 1836 1840 <span type="species:ncbi:10090">mice</span>
###xml 1891 1895 <span type="species:ncbi:10090">mice</span>
###xml 1937 1941 <span type="species:ncbi:10090">mice</span>
###xml 2192 2196 <span type="species:ncbi:10090">mice</span>
FIGURE 4.RSDP selectively impairs GABAB(1a,2) receptors located at glutamatergic terminals.A, the percentage of mEPSC and mIPSC frequency inhibition by baclofen (bac, 100 mum) and adenosine (adeno, 100 mum) under control condition (ACSF, white bars) and after incubation of acute hippocampal slices from wild-type (WT) mice with RSDP (40 nm, black bars) for 6 h. Baclofen was significantly less efficient in reducing the frequency of mEPSCs recorded from CA1 pyramidal neurons incubated with RSDP than from neurons incubated with ACSF (ACSF, 71.0 +/- 5.4% inhibition, n = 5; RSDP, 7.6 +/- 2.2% inhibition, n = 9; ***, p < 0.001, Kolmogorov-Smirnov; see also supplemental Table S2). RSDP was without effect on adenosine-mediated mEPSC frequency inhibition (ACSF, 67.0 +/- 5.3% inhibition, n = 5; RSDP, 76.0 +/- 3.0% inhibition, n = 9; supplemental Table S2). As an additional control, RSDP was also without effect on the baseline mEPSC frequency or amplitude (for values, see supplemental Table S3). RSDP did not affect the baclofen- or adenosinemediated inhibition of the mIPSCs frequency recorded from CA1 pyramidal neurons (for values, see supplemental Table S2). RSDP did not alter the amplitudes of Kir3 current responses induced by baclofen and adenosine in CA1 pyramidal neurons (n = 6 per condition). B, RSDP impairs the baclofen-mediated mEPSC frequency inhibition in 1b-/- mice (ACSF, 67.0 +/- 3.0% inhibition; RSDP, 6.0 +/- 2.0%; n = 4; ***, p < 0.001, Kolmogorov-Smirnov). Incubation with RSDP had no effect on baclofen- or adenosine-mediated effects on the mIPSC frequency (for values, see supplemental Table S2) or on Kir3 current amplitudes. Baclofen-induced Kir3 current responses were reduced in the 1b-/- when compared with wild-type mice, as described (22). C, baclofen failed to depress the mEPSCs frequency in 1a-/- mice due to the lack of GABAB heteroreceptors in these mice (22). The basal mEPSC frequency in 1a-/- mice was increased (for values, see supplemental Table S3), as reported previously (22). RSDP was without effect on the baclofen- or adenosine-mediated inhibition of the mIPSC frequency (for values, see supplemental Table S2) or on Kir3 currents in 1a-/- mice. All values are means +/- S.E.
###end p 28
###begin p 29
###xml 29 36 29 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RSDP selectively impairs GABA<sub>B(1a,2)</sub> receptors located at glutamatergic terminals.</bold>
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 153 156 153 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bac</italic>
###xml 164 165 163 164 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 182 187 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">adeno</italic>
###xml 195 196 193 194 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 229 239 227 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white bars</italic>
###xml 306 308 304 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 330 331 328 329 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 333 343 331 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 559 560 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 597 598 591 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 604 607 598 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 609 610 603 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 779 780 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 818 819 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1277 1278 1267 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1299 1300 1289 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1369 1372 1359 1362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1431 1432 1417 1418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1438 1441 1424 1427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 1443 1444 1429 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1709 1712 1695 1698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1762 1764 1748 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1767 1768 1753 1754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1823 1826 1809 1812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1855 1856 1841 1842 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1888 1890 1874 1876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1924 1927 1910 1913 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 2012 2014 1998 2000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 2179 2182 2165 2168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
###xml 1373 1377 <span type="species:ncbi:10090">mice</span>
###xml 1742 1746 <span type="species:ncbi:10090">mice</span>
###xml 1827 1831 <span type="species:ncbi:10090">mice</span>
###xml 1882 1886 <span type="species:ncbi:10090">mice</span>
###xml 1928 1932 <span type="species:ncbi:10090">mice</span>
###xml 2183 2187 <span type="species:ncbi:10090">mice</span>
RSDP selectively impairs GABAB(1a,2) receptors located at glutamatergic terminals.A, the percentage of mEPSC and mIPSC frequency inhibition by baclofen (bac, 100 mum) and adenosine (adeno, 100 mum) under control condition (ACSF, white bars) and after incubation of acute hippocampal slices from wild-type (WT) mice with RSDP (40 nm, black bars) for 6 h. Baclofen was significantly less efficient in reducing the frequency of mEPSCs recorded from CA1 pyramidal neurons incubated with RSDP than from neurons incubated with ACSF (ACSF, 71.0 +/- 5.4% inhibition, n = 5; RSDP, 7.6 +/- 2.2% inhibition, n = 9; ***, p < 0.001, Kolmogorov-Smirnov; see also supplemental Table S2). RSDP was without effect on adenosine-mediated mEPSC frequency inhibition (ACSF, 67.0 +/- 5.3% inhibition, n = 5; RSDP, 76.0 +/- 3.0% inhibition, n = 9; supplemental Table S2). As an additional control, RSDP was also without effect on the baseline mEPSC frequency or amplitude (for values, see supplemental Table S3). RSDP did not affect the baclofen- or adenosinemediated inhibition of the mIPSCs frequency recorded from CA1 pyramidal neurons (for values, see supplemental Table S2). RSDP did not alter the amplitudes of Kir3 current responses induced by baclofen and adenosine in CA1 pyramidal neurons (n = 6 per condition). B, RSDP impairs the baclofen-mediated mEPSC frequency inhibition in 1b-/- mice (ACSF, 67.0 +/- 3.0% inhibition; RSDP, 6.0 +/- 2.0%; n = 4; ***, p < 0.001, Kolmogorov-Smirnov). Incubation with RSDP had no effect on baclofen- or adenosine-mediated effects on the mIPSC frequency (for values, see supplemental Table S2) or on Kir3 current amplitudes. Baclofen-induced Kir3 current responses were reduced in the 1b-/- when compared with wild-type mice, as described (22). C, baclofen failed to depress the mEPSCs frequency in 1a-/- mice due to the lack of GABAB heteroreceptors in these mice (22). The basal mEPSC frequency in 1a-/- mice was increased (for values, see supplemental Table S3), as reported previously (22). RSDP was without effect on the baclofen- or adenosine-mediated inhibition of the mIPSC frequency (for values, see supplemental Table S2) or on Kir3 currents in 1a-/- mice. All values are means +/- S.E.
###end p 29
###begin p 30
###xml 29 36 29 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 0 81 0 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RSDP Selectively Impairs GABA<sub>B(1a,2)</sub> Receptors Located at Glutamatergic Terminals</italic>
###xml 138 139 138 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 305 306 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 299 306 299 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 554 555 554 555 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 568 569 568 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 562 569 562 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 658 659 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 804 805 804 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 798 805 798 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 914 915 914 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 917 919 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 984 985 984 985 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1003 1004 1003 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 997 1004 997 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1084 1085 1084 1085 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1129 1132 1129 1132 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1155 1158 1155 1158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1214 1215 1214 1215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1227 1229 1227 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 1230 1232 1230 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 1281 1288 1281 1288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 1323 1330 1323 1330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 1400 1407 1400 1407 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1b,2)</sub>
###xml 1507 1510 1507 1510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1576 1583 1576 1583 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 1619 1626 1619 1626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 1657 1660 1657 1660 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1767 1768 1767 1768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1761 1768 1761 1768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1837 1840 1837 1840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1855 1856 1855 1856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1849 1856 1849 1856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1923 1924 1923 1924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1917 1924 1917 1924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1980 1981 1980 1981 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1997 2000 1997 2000 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 2024 2025 2024 2025 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 2056 2059 2056 2059 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1b</sub>
###xml 2075 2076 2075 2076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 2069 2076 2069 2076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 2207 2210 2207 2210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-C</italic>
###xml 2199 2210 2199 2210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, <italic>A-C</italic></xref>
###xml 2285 2292 2285 2292 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 1511 1515 <span type="species:ncbi:10090">mice</span>
###xml 2001 2005 <span type="species:ncbi:10090">mice</span>
RSDP Selectively Impairs GABAB(1a,2) Receptors Located at Glutamatergic Terminals-We next investigated whether RSDP similarly impairs GABAB heteroreceptors in acute hippocampal slices. Under control conditions, baclofen significantly reduced the mEPSC frequency recorded from CA1 pyramidal neurons (Fig. 4A), whereas there was no significant change in the mEPSC amplitude distribution (not shown). Consistent with the results obtained with dissociated neurons, baclofen was ineffective in reducing the mEPSC frequency after incubation of slices with 40 nm RSDP (Fig. 4A). Baclofen is also described to inhibit the mIPSC frequency by acting at autoreceptors (5, 33). Although baclofen inhibited the frequency of mIPSC recorded from CA1 pyramidal neurons, RSDP was without effect on this inhibition (Fig. 4A). Likewise, RSDP did not alter the amplitude of Kir3 currents induced by baclofen in CA1 pyramidal neurons (9, 11, 22), demonstrating that RSDP has no effect on postsynaptic GABAB receptors (Fig. 4A). These data suggest that RSDP selectively interferes with the function of GABAB heteroreceptors, which incorporate the GABAB1a subunit. However, GABAB1a also contributes to autoreceptors and postsynaptic GABAB receptors (22-24). In the above experiments, RSDP effects on GABAB(1a,2) autoreceptors or postsynaptic GABAB(1a,2) receptors may remain undetected due to the concomitant action of GABAB(1b,2) receptors at GABAergic terminals and postsynaptic sites. We therefore used hippocampal slices of 1b-/- mice to address whether RSDP interferes with the activity of GABAB(1a,2) autoreceptors and postsynaptic GABAB(1a,2) receptors. We found that in 1b-/- slices, RSDP neither impaired autoreceptor responses nor impaired baclofen-activated Kir3 currents (Fig. 4B). In contrast, RSDP strongly impaired heteroreceptor responses in 1b-/- slices (Fig. 4B), thus corroborating the data obtained in wild-type slices (Fig. 4A). RSDP was without effect on pre- and postsynaptic GABAB responses in 1a-/- mice, in which all GABAB receptors incorporate the GABAB1b subunit (Fig. 4C). As a control, RSDP again failed to impair the actions of pre- and postsynaptic adenosine A1 receptors in all genotypes (Fig. 4, A-C). In summary, these results demonstrate that RSDP exclusively impairs GABAB(1a,2) receptors located at glutamatergic terminals.
###end p 30
###begin p 31
###xml 17 18 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 0 75 0 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RSDP Impairs GABA<sub>B</sub> Receptor-mediated Inhibition of Evoked Glutamate Release</italic>
###xml 106 107 106 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 750 751 750 751 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 837 838 837 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 843 844 843 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 829 844 829 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>A</italic> and <italic>B</italic></xref>
###xml 978 979 978 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 984 985 984 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 970 985 970 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>A</italic> and <italic>B</italic></xref>
###xml 1171 1172 1171 1172 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1273 1274 1273 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1279 1280 1279 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1265 1280 1265 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>A</italic> and <italic>B</italic></xref>
RSDP Impairs GABAB Receptor-mediated Inhibition of Evoked Glutamate Release-Activation of presynaptic GABAB receptors not only reduces the frequencies of mEPSCs and mIPSCs but also reduces the amplitudes of evoked EPSCs and IPSCs (7, 11, 22). The inhibitory effect of baclofen on spontaneous release is believed to be mechanistically distinct from its effect on evoked release (5, 7, 8, 34). It therefore was interesting to address whether the effect of RSDP on the control of spontaneous glutamate release generalizes to the evoked release. Specifically, we tested whether RSDP interferes with the baclofen-induced reduction in the amplitudes of evoked EPSCs recorded from CA1 pyramidal neurons (22). Incubation of acute hippocampal slices with 40 nm RSDP essentially abolished the reduction of the EPSC amplitudes by baclofen (Fig. 5, A and B). In contrast, RSDP did not influence the baclofen-induced reduction of IPSC amplitudes recorded from CA1 pyramidal neurons (Fig. 5, A and B). As a control, RSDP failed to interfere with the reduction of evoked EPSC and IPSC amplitudes mediated by adenosine A1 receptors. These data confirm that RSDP specifically acts at GABAB heteroreceptors and show that RSDP affects spontaneous as well as evoked glutamate release (Fig. 5, A and B).
###end p 31
###begin p 32
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 398 399 398 399 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 592 593 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 586 593 586 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 626 627 626 627 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 682 685 682 685 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 687 689 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 797 798 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 803 804 803 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 821 822 821 822 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 881 882 881 882 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 927 928 927 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
The tertiary structure of the SDs, which is fixed by two conserved intramolecular disulfide bridges, is critical for function (20). We produced a mutRSDP with serine substitutions of the first and fourth cysteine in each SD, which precludes disulfide bond formation (supplemental Fig. 2). We found that incubation of slices with mutRSDP or RSDP that was kept in a reduced state (treatment with 20 mm dithiothreitol) was without effect on the baclofen-induced reduction of evoked EPSC amplitudes, supporting that the binding function of RSDP is important for inhibiting heteroreceptors (Fig. 5A). Incubation of slices with 40 nm recombinant fibulin-2, a known binding partner of GABAB1a (19), did not interfere with the baclofen-induced inhibition of evoked glutamate release (supplemental Fig. 3, A and B). Moreover, 40 nm fibulin-2 did not neutralize the inhibitory action of 40 nm RSDP at heteroreceptors (supplemental Fig. 3C). It therefore appears that RSDP does not impair heteroreceptors by scavenging fibulin-2.
###end p 32
###begin p 33
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 118 9 118 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RSDP selectively impairs the baclofen-induced decrease of evoked EPSC amplitudes in acute hippocampal slices.</bold>
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 137 138 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black</italic>
###xml 248 251 248 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 274 275 273 274 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 297 298 295 296 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 371 372 369 370 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 408 409 406 407 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 513 514 511 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 591 592 588 589 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 615 616 611 612 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 754 755 748 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 793 794 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 800 803 792 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 805 806 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1069 1070 1059 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1104 1105 1092 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 9 1221 9 1207 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34"><bold>RSDP selectively impairs the baclofen-induced decrease of evoked EPSC amplitudes in acute hippocampal slices.</bold><italic>A</italic>, average traces (<italic>n</italic> = 100 events) depicting evoked EPSCs and IPSCs in CA1 pyramidal neurons before (<italic>black</italic>) and after inhibition (<italic>red</italic>) with baclofen (100 &#956;<sc>m</sc>) or adenosine (100 &#956;<sc>m</sc>). Recordings were after a 6-h incubation of slices with ACSF, RSDP (40 n<sc>m</sc>), reduced RSDP (treatment with 20 m<sc>m</sc> dithiothreitol for 2 h prior to slice application), and RSDP with mutated disulfide bridges (mutRSDP). <italic>B</italic>, summary histograms of the inhibition of EPSCs and IPSCs by baclofen (100 &#956;<sc>m</sc>) and adenosine (100 &#956;<sc>m</sc>) in CA1 pyramidal neurons. In the presence of RSDP, baclofen was less efficient in reducing EPSC amplitudes (ACSF, 85 &#177; 4% inhibition, <italic>n</italic> = 6; RSDP, 12.5 &#177; 3.5% inhibition, <italic>n</italic> = 6; <sup>***</sup>, <italic>p</italic> &lt; 0.001, analysis of variance). In contrast, reduced RSDP or mutRSDP were without effect on the baclofen-induced decrease of EPSC amplitudes. All treatment conditions did not impair the adenosine-mediated decrease in EPSC amplitudes (ACSF, 83 &#177; 2% inhibition, <italic>n</italic> = 6; RSDP, 85 &#177; 3% inhibition, <italic>n</italic> = 6). RSDP did not impair the baclofen- or adenosine-mediated inhibition of evoked IPSCs. Values are means &#177; S.E.</p>
###xml 9 1221 9 1207 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34"><bold>RSDP selectively impairs the baclofen-induced decrease of evoked EPSC amplitudes in acute hippocampal slices.</bold><italic>A</italic>, average traces (<italic>n</italic> = 100 events) depicting evoked EPSCs and IPSCs in CA1 pyramidal neurons before (<italic>black</italic>) and after inhibition (<italic>red</italic>) with baclofen (100 &#956;<sc>m</sc>) or adenosine (100 &#956;<sc>m</sc>). Recordings were after a 6-h incubation of slices with ACSF, RSDP (40 n<sc>m</sc>), reduced RSDP (treatment with 20 m<sc>m</sc> dithiothreitol for 2 h prior to slice application), and RSDP with mutated disulfide bridges (mutRSDP). <italic>B</italic>, summary histograms of the inhibition of EPSCs and IPSCs by baclofen (100 &#956;<sc>m</sc>) and adenosine (100 &#956;<sc>m</sc>) in CA1 pyramidal neurons. In the presence of RSDP, baclofen was less efficient in reducing EPSC amplitudes (ACSF, 85 &#177; 4% inhibition, <italic>n</italic> = 6; RSDP, 12.5 &#177; 3.5% inhibition, <italic>n</italic> = 6; <sup>***</sup>, <italic>p</italic> &lt; 0.001, analysis of variance). In contrast, reduced RSDP or mutRSDP were without effect on the baclofen-induced decrease of EPSC amplitudes. All treatment conditions did not impair the adenosine-mediated decrease in EPSC amplitudes (ACSF, 83 &#177; 2% inhibition, <italic>n</italic> = 6; RSDP, 85 &#177; 3% inhibition, <italic>n</italic> = 6). RSDP did not impair the baclofen- or adenosine-mediated inhibition of evoked IPSCs. Values are means &#177; S.E.</p></caption>
###xml 1221 1221 1207 1207 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0470855220005"/>
###xml 0 1221 0 1207 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="34"><bold>RSDP selectively impairs the baclofen-induced decrease of evoked EPSC amplitudes in acute hippocampal slices.</bold><italic>A</italic>, average traces (<italic>n</italic> = 100 events) depicting evoked EPSCs and IPSCs in CA1 pyramidal neurons before (<italic>black</italic>) and after inhibition (<italic>red</italic>) with baclofen (100 &#956;<sc>m</sc>) or adenosine (100 &#956;<sc>m</sc>). Recordings were after a 6-h incubation of slices with ACSF, RSDP (40 n<sc>m</sc>), reduced RSDP (treatment with 20 m<sc>m</sc> dithiothreitol for 2 h prior to slice application), and RSDP with mutated disulfide bridges (mutRSDP). <italic>B</italic>, summary histograms of the inhibition of EPSCs and IPSCs by baclofen (100 &#956;<sc>m</sc>) and adenosine (100 &#956;<sc>m</sc>) in CA1 pyramidal neurons. In the presence of RSDP, baclofen was less efficient in reducing EPSC amplitudes (ACSF, 85 &#177; 4% inhibition, <italic>n</italic> = 6; RSDP, 12.5 &#177; 3.5% inhibition, <italic>n</italic> = 6; <sup>***</sup>, <italic>p</italic> &lt; 0.001, analysis of variance). In contrast, reduced RSDP or mutRSDP were without effect on the baclofen-induced decrease of EPSC amplitudes. All treatment conditions did not impair the adenosine-mediated decrease in EPSC amplitudes (ACSF, 83 &#177; 2% inhibition, <italic>n</italic> = 6; RSDP, 85 &#177; 3% inhibition, <italic>n</italic> = 6). RSDP did not impair the baclofen- or adenosine-mediated inhibition of evoked IPSCs. Values are means &#177; S.E.</p></caption><graphic xlink:href="zbc0470855220005"/></fig>
FIGURE 5.RSDP selectively impairs the baclofen-induced decrease of evoked EPSC amplitudes in acute hippocampal slices.A, average traces (n = 100 events) depicting evoked EPSCs and IPSCs in CA1 pyramidal neurons before (black) and after inhibition (red) with baclofen (100 mum) or adenosine (100 mum). Recordings were after a 6-h incubation of slices with ACSF, RSDP (40 nm), reduced RSDP (treatment with 20 mm dithiothreitol for 2 h prior to slice application), and RSDP with mutated disulfide bridges (mutRSDP). B, summary histograms of the inhibition of EPSCs and IPSCs by baclofen (100 mum) and adenosine (100 mum) in CA1 pyramidal neurons. In the presence of RSDP, baclofen was less efficient in reducing EPSC amplitudes (ACSF, 85 +/- 4% inhibition, n = 6; RSDP, 12.5 +/- 3.5% inhibition, n = 6; ***, p < 0.001, analysis of variance). In contrast, reduced RSDP or mutRSDP were without effect on the baclofen-induced decrease of EPSC amplitudes. All treatment conditions did not impair the adenosine-mediated decrease in EPSC amplitudes (ACSF, 83 +/- 2% inhibition, n = 6; RSDP, 85 +/- 3% inhibition, n = 6). RSDP did not impair the baclofen- or adenosine-mediated inhibition of evoked IPSCs. Values are means +/- S.E.
###end p 33
###begin p 34
###xml 0 109 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RSDP selectively impairs the baclofen-induced decrease of evoked EPSC amplitudes in acute hippocampal slices.</bold>
###xml 109 110 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 128 129 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 210 215 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black</italic>
###xml 239 242 239 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 265 266 264 265 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 288 289 286 287 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 362 363 360 361 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 399 400 397 398 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 504 505 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 582 583 579 580 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 606 607 602 603 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 745 746 739 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 784 785 776 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 791 794 783 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 796 797 788 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1060 1061 1050 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1095 1096 1083 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
RSDP selectively impairs the baclofen-induced decrease of evoked EPSC amplitudes in acute hippocampal slices.A, average traces (n = 100 events) depicting evoked EPSCs and IPSCs in CA1 pyramidal neurons before (black) and after inhibition (red) with baclofen (100 mum) or adenosine (100 mum). Recordings were after a 6-h incubation of slices with ACSF, RSDP (40 nm), reduced RSDP (treatment with 20 mm dithiothreitol for 2 h prior to slice application), and RSDP with mutated disulfide bridges (mutRSDP). B, summary histograms of the inhibition of EPSCs and IPSCs by baclofen (100 mum) and adenosine (100 mum) in CA1 pyramidal neurons. In the presence of RSDP, baclofen was less efficient in reducing EPSC amplitudes (ACSF, 85 +/- 4% inhibition, n = 6; RSDP, 12.5 +/- 3.5% inhibition, n = 6; ***, p < 0.001, analysis of variance). In contrast, reduced RSDP or mutRSDP were without effect on the baclofen-induced decrease of EPSC amplitudes. All treatment conditions did not impair the adenosine-mediated decrease in EPSC amplitudes (ACSF, 83 +/- 2% inhibition, n = 6; RSDP, 85 +/- 3% inhibition, n = 6). RSDP did not impair the baclofen- or adenosine-mediated inhibition of evoked IPSCs. Values are means +/- S.E.
###end p 34
###begin title 35
DISCUSSION
###end title 35
###begin p 36
###xml 31 34 31 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 51 53 51 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 75 78 75 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 102 104 102 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 155 158 155 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 358 360 358 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 470 473 470 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 726 733 726 733 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 783 790 783 790 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(B1a,2)</sub>
###xml 825 832 825 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(B1a,2)</sub>
###xml 1154 1156 1154 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
###xml 1157 1159 1157 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 1261 1264 1261 1264 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1266 1268 1266 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 1378 1381 1378 1381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
###xml 1581 1584 1581 1584 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1a</sub>
In this study, we describe GABAB1j, a secreted GABAB1 subunit isoform. GABAB1j, like all secreted GABAB1 isoforms (14-16), contains the SDs present in GABAB1a. Naturally occurring soluble SDs of other membrane-bound receptors were shown to exert physiologically relevant dominant-negative effects (25, 26). We therefore asked whether the SDs of secreted GABAB1 isoforms could act similarly and scavenge a putative extracellular binding partner of the membrane-bound GABAB1a subunit. Consistent with this proposal, we found that RSDP, a recombinant protein consisting of the two SDs, binds with low nanomolar affinity to specific binding sites in neuronal membranes. We also found that RSDP interferes with the activity of GABAB(1a,2) heteroreceptors, whereas having no effect at GABA(B1a,2) autoreceptors or postsynaptic GABA(B1a,2) receptors. These results imply that functionally relevant SD binding sites exist at the cell surface of glutamatergic terminals. In this context, it is interesting to note that other neurotransmitter receptors were recently shown to bind to extracellular partners that regulate their synaptic localization and functions (35-37). In our experiments, the extracellular matrix protein fibulin-2, which binds to the first SD of GABAB1a (19), was without effect on heteroreceptor function. We did not observe that RSDP co-immunoprecipitates with GABAB1a after co-expression in HEK293 cells, suggesting that SDs do not recruit heteroreceptors through homophilic interactions either (data not shown). Therefore, the auxiliary factor binding to SDs of GABAB1a at the cell surface remains to be identified.
###end p 36
###begin p 37
###xml 12 13 12 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 187 194 187 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B(1a,2)</sub>
###xml 292 299 292 299 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(B1a,2)</sub>
###xml 334 341 334 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(B1a,2)</sub>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 375 382 375 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 419 426 419 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(B1a,2)</sub>
###xml 536 537 536 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref38">38</xref>
###xml 599 606 599 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(B1a,2)</sub>
###xml 641 648 641 648 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(B1a,2)</sub>
###xml 705 712 705 712 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(B1a,2)</sub>
###xml 781 782 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 775 782 775 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 989 996 989 996 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(B1a,2)</sub>
###xml 1335 1336 1335 1336 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
How are GABAB heteroreceptors inactivated following RSDP exposure? First of all, we exclude that RSDP acts as a competitive antagonist of GABAB receptors because RSDP did not inhibit GABAB(1a,2)-mediated Kir3 responses in HEK293 cells (data not shown), nor did it inhibit the function of GABA(B1a,2) autoreceptors or postsynaptic GABA(B1a,2) receptors in hippocampal slices (Fig. 4B). It also appears unlikely that GABA(B1a,2) receptors rapidly internalize as a consequence of disrupting an extracellular interaction since neuronal GABAB receptors do not efficiently internalize (38). Moreover, GABA(B1a,2) autoreceptors or postsynaptic GABA(B1a,2) receptors are not affected by RSDP, suggesting that GABA(B1a,2) receptors are functional in the absence of an SD interaction (Fig. 4B). Since heteroreceptor impairment is seen within minutes of RSDP application to dissociated hippocampal neurons in culture, we also consider it unlikely that RSDP interferes with the axonal delivery of GABA(B1a,2) receptors. Most likely, the extracellular binding partner of the SDs acts as a diffusion trap that keeps heteroreceptors and elements of the release machinery in close proximity. RSDP may scavenge the SD binding partner and thereby promote lateral diffusion of heteroreceptors. This may explain why RSDP concomitantly interferes with GABAB effectors involved in the inhibition of spontaneous and evoked release.
###end p 37
###begin p 38
###xml 32 34 32 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 53 56 53 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1j</sub>
###xml 244 246 244 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B1</sub>
###xml 402 403 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref39">39</xref>
###xml 615 623 <span type="species:ncbi:9606">patients</span>
Our data show that secreted GABAB1 isoforms like GABAB1j could, in principle, adjust the level of presynaptic inhibition at glutamatergic terminals. It therefore will be interesting to address whether the production of the various secreted GABAB1 isoforms is regulated in response to physiological stimuli. Of importance, our findings may also be exploited therapeutically. Drug development in the GABAB field was largely hampered because receptor subtypes cannot be distinguished pharmacologically. For example, it would be desirable to selectively inhibit heteroreceptors to boost excitatory neurotransmission in patients with cognitive impairments (39). Our experiments now directly show that this is possible by targeting the SDs.
###end p 38
###begin title 39
Supplementary Material
###end title 39
###begin title 40
[Supplemental Data]
###end title 40
###begin p 41
We thank R. Seddik, H. R. Brenner, and K. Vogt for critical reading of the manuscript.
###end p 41
###begin p 42
###xml 334 349 <span type="species:ncbi:10029">Chinese hamster</span>
The abbreviations used are: GABA, gamma-aminobutyric acid; EPSC, excitatory postsynaptic current; mEPSC, miniature EPSC; IPSC, inhibitory postsynaptic current; mIPSC, miniature IPSC; SD, sushi domain; RSDP, recombinant SD protein; mutRSDP, mutant RSDP; ACSF, artificial cerebrospinal fluid; MES, 4-morpholineethanesulfonic acid; CHO, Chinese hamster ovary.
###end p 42

